11002a

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 4-6-2004

Art Unit: 1654 Phone Number 571-272-0969 Serial Number: 10/030,388

Mail Box and Bldg/Room Location: REM 3D11 (mailbox), 3D19 (office) Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Radiolabeled Mammalian Tachykinin Peptide Analogue

Inventors (please provide full names): P. Armua

CAFE

Earliest Priority Filing Date: 5-21-2002.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search SEQ ID NO:1 (F X GLM) in STN, in the U.S. patent application sequence database (pending, published, and issued) and in Geneseq/Swissprot/PIR. Please require any hits to have 15 or fewer residues.

Thank you.

JR

****

(FILE 'REGISTRY' ENTERED AT 14:59:16 ON 07 APR 2004)
L5 4109 S F[FIV]GLM/SQSP
L6 2407 S L5 AND SQL=<15

FILE 'HCAPLUS' ENTERED AT 15:00:15 ON 07 APR 2004
L5 4109 SEA FILE=REGISTRY ABB=ON PLU=ON F[FIV]GLM/SQSP
L6 2407 SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND SQL=<15
L7 14575 SEA FILE=HCAPLUS ABB=ON PLU=ON L6
L9 113 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (RADIOLABEL? OR RADIO LABEL?)
L10 51 SEA FILE=HCAPLUS ABB=ON PLU=ON L9 AND TACHYKININ
L16 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND MAMMAL?

L16 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 03 Sep 2002
ACCESSION NUMBER: 2002:662100 HCAPLUS
DOCUMENT NUMBER: 138:19555
TITLE: Central neuropeptide systems and respiratory control during development
AUTHOR(S): Moss, Immanuela Rave; Laferriere, Andre
CORPORATE SOURCE: Development Respiratory Laboratory, The Research Institute of the McGill University Health Centre, Montreal, QC, H3H 1P3, Can.
SOURCE: Respiratory Physiology & Neurobiology (2002), 131(1-2), 15-27
CODEN: RPNEAV; ISSN: 1569-9048
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. The substance P/neurotachykinin-1 (NK-1) and the μ-opioid G protein-coupled receptor systems endow brain-stem respiratory regions and display discrete developmental patterns. Hypoxia-induced neuropeptide release may increase receptor endocytosis, reducing receptor accessibility to ligands. We wondered whether the attenuated respiratory response to hypoxia of developing piglets after single or repeated daily hypoxic exposure is influenced by differential endocytosis of NK-1 vs. μ-opioid receptors. Whereas the long-term (24 h) response of both receptors to recurrent hypoxia in piglet brainstem is similar, i.e. upregulation, the short-term (5 min) response to single or recurrent hypoxia, albeit in rats, is different: **radiolabeled** NK-1 receptors are greatly reduced, suggesting enhanced endocytosis, but μ-opioid receptors remain unchanged, implying unaltered endocytosis. If confirmed in piglet brainstem, this difference would produce relatively more available μ-opioid receptors to opioid peptides in hypoxia that might contribute to the attenuated respiratory responses to single and repeated hypoxia during development.

IT **33507-63-0**, Substance P
RL: BSU (Biological study, unclassified); BIOL (Biological study) (central neuropeptide systems and respiratory control during development)
REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Searcher : Shears 571-272-2528

L16 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 12 Jan 2001
ACCESSION NUMBER: 2001:31364 HCAPLUS
DOCUMENT NUMBER: 134:82815
TITLE: A **radiolabeled mammalian tachykinin** peptide analogue
INVENTOR(S): Ortiz Armua, Pedro
PATENT ASSIGNEE(S): Spain
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002021	A2	20010111	WO 2000-IB1260	20000705
WO 2001002021	A3	20020207		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1196200	A2	20020417	EP 2000-954837	20000705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 2002000096	A	20030404	ZA 2002-96	20020104

PRIORITY APPLN. INFO.: ES 1999-1489 A 19990705
WO 2000-IB1260 W 20000705

AB A **radiolabeled mammalian tachykinin** peptide analog; use of the analog for **mammalian** in vivo **tachykinin** peptide receptor imaging; and a diagnostic kit comprising the analog are described. 99mTc-labeled substance P, prepared using 2-iminothiolane as linker, showed good uptake in salivary glands of mice.

IT **33507-63-0DP**, Substance P peptide, 99mTc-labeled
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(**radiolabeled mammalian tachykinin** peptide analog for diagnostic imaging)

IT **4846-01-9D**, Phe-Ile-Gly-Leu-Met-NH2, **radiolabeled** derivs. **51165-05-0D**, Phe-Phe-Gly-Leu-Met-NH2, **radiolabeled** derivs. **86933-74-6D**, Neurokinin A, **radiolabeled 86933-74-6D**, Neurokinin A, **radiolabeled** derivs. **86933-75-7D**, Neurokinin B (swine spinal cord), **radiolabeled 89671-31-8D**, Phe-Val-Gly-Leu-Met-NH2, **radiolabeled** derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**radiolabeled mammalian tachykinin** peptide analog for diagnostic imaging)

Searcher : Shears 571-272-2528

L16 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 17 Feb 1990
ACCESSION NUMBER: 1990:49215 HCAPLUS
DOCUMENT NUMBER: 112:49215
TITLE: Identification of immunoreactive substance P in human and other **mammalian** endothelial cells
AUTHOR(S): Linnik, Matthew D.; Moskowitz, Michael A.
CORPORATE SOURCE: Neurol. Neurosurg. Serv., Massachusetts Gen. Hosp., Boston, MA, 02114, USA
SOURCE: Peptides (New York, NY, United States) (1989), 10(5), 957-62
CODEN: PPTDD5; ISSN: 0196-9781
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The existence of the vasodilatory **tachykinin** substance P within endothelial cell scrapings from human, rat, and dog thoracic aorta and human pial arteries with values ranging from 1.0 (rat aorta) to 1.9 (dog aorta) fmol/mg protein is described. The immunoreactive component eluted with a retention time identical to that of **radiolabeled** substance P when analyzed by HPLC combined with RIA. Cultured endothelial cells from bovine cerebral microvessels contained measurable levels of substance P in passages 3-8, suggesting the likelihood that these cells synthesize substance P. However, the level of gene expression must be low since efforts to demonstrate the presence of preprotachykinin mRNA by Northern blot anal. of dog and rat aortic endothelial cell RNA or by RNase protection anal. of rat aortic endothelial cell RNA were not successful.
IT **33507-63-0**, Substance P
RL: BIOL (Biological study)
(in vascular endothelium, of humans and other **mammals**)

L16 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 30 Apr 1989
ACCESSION NUMBER: 1989:148516 HCAPLUS
DOCUMENT NUMBER: 110:148516
TITLE: Substance P and substance K receptor binding sites in the human gastrointestinal tract: localization by autoradiography
AUTHOR(S): Gates, T. S.; Zimmerman, R. P.; Mantyh, C. R.; Vigna, S. R.; Maggio, J. E.; Welton, M. L.; Passaro, E. P., Jr.; Mantyh, P. W.
CORPORATE SOURCE: Cent. Ulcer Res. Educ., VA Med. Cent. Wadsworth, Los Angeles, CA, 90073, USA
SOURCE: Peptides (New York, NY, United States) (1988), 9(6), 1207-19
CODEN: PPTDD5; ISSN: 0196-9781
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Quant. receptor autoradiog. was used to localize and quantify the distribution of binding sites for 125I-**radiolabeled** substance P (SP), substance K (SK) and neuromedin K (NK) in the human gastrointestinal (GI) tract using histol. normal tissue obtained from uninvolved margins of resections for carcinoma. The

distribution of SP and SK binding sites is different for each gastrointestinal segment examined Specific SP binding sites are expressed by arterioles and venules, myenteric plexus, external circular muscle, external longitudinal muscle, muscularis mucosa, epithelial cells of the mucosa, and the germinal centers of lymph nodules. SK binding sites are distributed in a pattern distinct from SP binding sites and are localized to the external circular muscle, external longitudinal muscle, and the muscularis mucosa. Binding sites for NK were not detected in any part of the human GI tract. Thus, surgical specimens from the human GI tract can be effectively processed for quant. receptor autoradiog. Of the 3 **mammalian tachykinins** tested, SP and SK, but not NK, binding sites are expressed in detectable levels in the human GI tract. Although SK receptor binding sites are expressed almost exclusively by smooth muscle, SP binding sites are expressed by smooth muscle cells, arterioles, venules, epithelial cells of the mucosa and cells associated with lymph nodules; both SP and SK binding sites expressed by smooth muscle are more stable than are SP binding sites expressed by blood vessels, lymph nodules, and mucosal cells.

IT **86933-75-7**, Neuromedin K
RL: PROC (Process)
(binding of, by gastrointestinal tract of human)

IT **33507-63-0**, Substance P **86933-74-6**
RL: BIOL (Biological study)
(receptors for, of gastrointestinal tract of human, localization of)

L16 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 01 Nov 1986
ACCESSION NUMBER: 1986:546964 HCAPLUS
DOCUMENT NUMBER: 105:146964
TITLE: Characterization of a neurokinin B receptor site in rat brain using a highly selective radioligand
AUTHOR(S): Laufer, Ralph; Gilon, Chaim; Chorev, Michael; Selinger, Zvi
CORPORATE SOURCE: Otto Loewi Cent. Neurobiol., Inst. Life Sci., Jerusalem, 91904, Israel
SOURCE: Journal of Biological Chemistry (1986), 261(22), 10257-63
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A **tachykinin** receptor subtype (SP-N), whose preferred ligand is the **mammalian** neuropeptide neurokinin B [**86933-75-7**], was investigated with the **radiolabeled** peptide 5-11-Nα-([125I]desamino-3-iodotyrosyl)-[Asp5,6-N-methyl-Phe8]-substance P (I) [**104499-96-9**], which selectively interacts with the SP-N receptor subtype. The binding of I to rat cerebral cortex membranes was studied under conditions that minimized nonspecific binding. Unlike other **tachykinin** receptor probes, this radioligand is not degraded during the binding experiment Binding of I is reversible, saturable, and of high affinity (dissociation constant = 0.9 nM). The radioligand labels a single class of binding site (122 fmol binding sites/mg of protein), as indicated by a linear Scatchard plot and a Hill coefficient close to unity (1.05).

The pharmacol. specificity of this binding site corresponds to that of the neuronal SP-N receptor in guinea pig ileum myenteric plexus, which was determined by a functional bioassay. Among various rat brain regions, the highest binding was observed in the cerebral cortex, olfactory bulb, hypothalamus, and hippocampus. The results suggest the existence and specific distribution of a neurokinin B receptor site of the SP-N type in rat brain. I is the 1st selective and potent probe for this receptor and is thus an important tool for further studies of its distribution, regulation, and functional role.

IT **103445-39-2**
RL: PROC (Process)
(neurokinin B receptor binding of, in brain)

IT **104499-96-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and neurokinin B receptor characterization with)

IT **104499-97-0**
RL: PROC (Process)
(radioiodination and neurokinin B receptor binding of)

IT **86933-75-7**
RL: BIOL (Biological study)
(receptor for, of brain, selective probe for)

E1 THROUGH E9 ASSIGNED

FILE 'REGISTRY' ENTERED AT 15:07:34 ON 07 APR 2004
L18 9 SEA FILE=REGISTRY ABB=ON PLU=ON (33507-63-0/BI OR 86933-74-6/BI OR 86933-75-7/BI OR 103445-39-2/BI OR 104499-96-9/BI OR 104499-97-0/BI OR 4846-01-9/BI OR 51165-05-0/BI OR 89671-31-8/BI)

=> s l18 and l5
L20 9 L18 AND L5

L20 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **104499-97-0** REGISTRY
CN L-Methioninamide, L-α-aspartyl-L-α-aspartyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Aminosenktide
SQL 7

SEQ 1 DDFFGLM
=====
HITS AT: 3-7

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:298650

REFERENCE 2: 130:119984

REFERENCE 3: 130:20972

Searcher : Shears 571-272-2528

REFERENCE 4: 129:131634

REFERENCE 5: 125:318273

REFERENCE 6: 120:210557

REFERENCE 7: 120:46561

REFERENCE 8: 120:24074

REFERENCE 9: 118:205901

REFERENCE 10: 118:33494

L20 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **104499-96-9** REGISTRY
CN L-Methioninamide, N-[3-[4-hydroxy-3-(iodo-125I)phenyl]-1-oxopropyl]-L-α-aspartyl-L-α-aspartyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
SQL 7

SEQ 1 DDFFGLM
=====
HITS AT: 3-7

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 105:146964

L20 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **103445-39-2** REGISTRY
CN L-Methioninamide, 5-oxo-L-prolyl-L-phenylalanyl-N-methyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
SQL 6

SEQ 1 XFFGLM
=====
HITS AT: 2-6

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:25326

REFERENCE 2: 119:181203

REFERENCE 3: 110:166270

REFERENCE 4: 109:205353

REFERENCE 5: 109:17666

REFERENCE 6: 107:229502

REFERENCE 7: 106:150010

REFERENCE 8: 105:146964

Searcher : Shears 571-272-2528

REFERENCE 9: 105:57318

L20 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **89671-31-8** REGISTRY
CN L-Methioninamide, L-phenylalanyl-L-valylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-10-Neurokinin α
CN Phe-Val-Gly-Leu-Met-NH2
CI COM
SQL 5

SEQ 1 FVGLM
=====
HITS AT: 1-5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 134:82815

REFERENCE 2: 133:190228

REFERENCE 3: 124:165481

REFERENCE 4: 122:151508

REFERENCE 5: 121:108267

REFERENCE 6: 116:121078

REFERENCE 7: 113:224635

REFERENCE 8: 104:168810

REFERENCE 9: 104:142380

REFERENCE 10: 103:196387

L20 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **86933-75-7** REGISTRY
CN Neurokinin B (swine spinal cord) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Kassinin, 2-L-methionine-3-L-histidine-4-de-L-lysine-5-de-L-serine-7-L-phenylalanine-
OTHER NAMES:
CN L-Methioninamide, L-α-aspartyl-L-methionyl-L-histidyl-L-α-aspartyl-L-phenylalanyl-L-phenylalanyl-L-valylglycyl-L-leucyl-
CN Neurokinin β
CN Neurokinin β (pig spinal cord)
CN Neurokinin B (human)
CN Neurokinin B (pig spinal cord)
CN Neurokinin B (porcine)
CN Neuromedin K
CN Neuromedin K (pig spinal cord)

CN Porcine neurokinin B
CN Zneurok1 (human)
CI COM
SQL 10

SEQ 1 DMHDFFVGLM
=====
HITS AT: 6-10

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:174859

REFERENCE 2: 140:157919

REFERENCE 3: 140:71480

REFERENCE 4: 140:71475

REFERENCE 5: 139:391722

REFERENCE 6: 139:375562

REFERENCE 7: 139:362106

REFERENCE 8: 139:286548

REFERENCE 9: 139:224854

REFERENCE 10: 139:208098

L20 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **86933-74-6** REGISTRY
CN Neurokinin A (swine spinal cord) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Kassinin, 1-de-L-aspartic acid-2-de-L-valine-3-L-histidine-5-L-threonine-7-L-serine-
OTHER NAMES:
CN L-Methioninamide, L-histidyl-L-lysyl-L-threonyl-L-α-aspartyl-L-seryl-L-phenylalanyl-L-valylglycyl-L-leucyl-
CN Neurokinin α
CN Neurokinin α (pig spinal cord)
CN Neurokinin α (porcine)
CN Neurokinin A
CN Neurokinin A (alligator)
CN Neurokinin A (pig spinal cord)
CN Neurokinin A (Python molurus)
CN Neuromedin L
CN Neuromedin L (pig spinal cord)
CN Porcine neurokinin A
CN Substance K
CI COM
SQL 10

SEQ 1 HKTDSFVGLM
=====

HITS AT: 6-10

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:229875

REFERENCE 2: 140:193438

REFERENCE 3: 140:193061

REFERENCE 4: 140:174869

REFERENCE 5: 140:174859

REFERENCE 6: 140:157919

REFERENCE 7: 140:140827

REFERENCE 8: 140:123112

REFERENCE 9: 140:107276

REFERENCE 10: 140:71486

L20 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **51165-05-0** REGISTRY
CN L-Methioninamide, L-phenylalanyl-L-phenylalanylglycyl-L-leucyl-
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7-11-Substance P
CN Phe-Phe-Gly-Leu-Met-NH2
CN Substance P pentapeptide
CI COM
SQL 5

SEQ 1 FFGLM
=====
HITS AT: 1-5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 139:341728

REFERENCE 2: 139:144282

REFERENCE 3: 138:21218

REFERENCE 4: 137:195720

REFERENCE 5: 136:366698

REFERENCE 6: 136:260222

REFERENCE 7: 136:227036

REFERENCE 8: 135:283312

REFERENCE 9: 134:82815

REFERENCE 10: 133:190228

L20 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **33507-63-0** REGISTRY
CN Substance P (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020037833 SEQID: 1 unclaimed sequence
CN 21: PN: WO0181408 SEQID: 44 claimed protein
CN 690: PN: WO2004005342 PAGE: 46 claimed protein
CN L-Methioninamide, L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl-
CN Neurokinin P
CN Substance P (1-11)
CN Substance P (peptide)
CN Substance P (smooth-muscle stimulant)
CI COM
SQL 11

SEQ 1 RPKPQQFFGL M
==== =
HITS AT: 7-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:234337

REFERENCE 2: 140:233882

REFERENCE 3: 140:233683

REFERENCE 4: 140:233682

REFERENCE 5: 140:233642

REFERENCE 6: 140:233061

REFERENCE 7: 140:232998

REFERENCE 8: 140:231826

REFERENCE 9: 140:230888

REFERENCE 10: 140:229887

L20 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN **4846-01-9** REGISTRY
CN L-Methioninamide, L-phenylalanyl-L-isoleucylglycyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methioninamide, L-phenylalanyl-L-isoleucylglycyl-L-leucyl-, L- (7CI)
CN Phyllomedusin, 1-de(5-oxo-L-proline)-2-de-L-asparagine-3-de-L-proline-4-de-L-asparagine-5-de-L-arginine- (8CI)
OTHER NAMES:

CN Eledoisin(7-11)
CN Phe-Ile-Gly-Leu-Met-NH2
CI COM
SQL 5

SEQ 1 FIGLM
=====
HITS AT: 1-5

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 134:82815

REFERENCE 2: 124:165481

REFERENCE 3: 122:151508

REFERENCE 4: 113:224635

REFERENCE 5: 112:51088

REFERENCE 6: 99:116778

REFERENCE 7: 91:21126

REFERENCE 8: 90:204506

REFERENCE 9: 88:23378

REFERENCE 10: 77:13876

FILE 'HOME' ENTERED AT 15:08:24 ON 07 APR 2004

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: April 7, 2004, 09:21:32 ; Search time 39 Seconds
(without alignments)
40.451 Million cell updates/sec

Title: US-10-030-388A-1
Perfect score: 22
Sequence: 1 FXGLM 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 3954

Minimum DB seq length: 0
Maximum DB seq length: 15

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : SPTREMBL_25:*
1: sp_archea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phage:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_rvirus:*
16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description

1	20	90.9	11	5	Q9UAR8	Q9uar8 aedes aegyp
2	18	81.8	15	11	Q924T1	Q924t1 rattus norv
3	15	68.2	10	8	Q35013	Q35013 meloidogyne
4	15	68.2	14	8	Q8M099	Q8m099 tockus nasu
5	15	68.2	15	8	Q9XLJ8	Q9xlj8 grus leucog
6	15	68.2	15	8	Q9TH03	Q9th03 grus paradi
7	14	63.6	15	2	Q9R541	Q9r541 mycobacteri
8	13	59.1	11	2	Q9R446	Q9r446 neisseria g
9	12	54.5	8	13	P82079	P82079 limnodynast
10	12	54.5	9	6	Q8MJN1	Q8mjn1 cebuella py
11	12	54.5	9	6	Q8MJN6	Q8mjn6 aotus azara
12	12	54.5	9	6	Q8MJN8	Q8mjn8 cebus apell
13	12	54.5	9	6	Q8MJN2	Q8mjn2 callithrix
14	12	54.5	9	6	Q8MJN9	Q8mjn9 ateles fusc
15	12	54.5	9	6	Q8MJN5	Q8mjn5 saguinus fu
16	12	54.5	9	6	Q8MJN3	Q8mjn3 callimico g
17	12	54.5	9	6	Q8MJN7	Q8mjn7 saimiri sci
18	12	54.5	9	6	Q8MJN4	Q8mjn4 leontopithe
19	12	54.5	9	15	Q85599	Q85599 moloney mur
20	12	54.5	10	5	Q25356	Q25356 locusta mig
21	12	54.5	10	5	Q25355	Q25355 locusta mig
22	12	54.5	10	13	P82080	P82080 limnodynast
23	12	54.5	10	13	P82084	P82084 limnodynast
24	12	54.5	11	6	Q9TRX0	Q9trx0 sus scrofa
25	12	54.5	11	7	O77872	O77872 oreochromis
26	12	54.5	11	7	O77873	O77873 oreochromis
27	12	54.5	11	7	O77871	O77871 oreochromis
28	12	54.5	12	2	Q53183	Q53183 rhodococcus
29	12	54.5	12	2	Q93UU4	Q93uu4 escherichia
30	12	54.5	12	6	Q9N2B9	Q9n2b9 gorilla gor
31	12	54.5	12	6	Q9N2B8	Q9n2b8 pongo pygma
32	12	54.5	12	6	Q9N2C0	Q9n2c0 pan troglod
33	12	54.5	12	6	P83127	P83127 bos indicus
34	12	54.5	12	10	Q9SYT4	Q9syt4 arabidopsis
35	12	54.5	12	10	Q02320	Q02320 pinus sylve
36	12	54.5	12	10	Q38715	Q38715 arachis hyp
37	12	54.5	12	10	Q02319	Q02319 pinus sylve
38	12	54.5	12	11	O54970	O54970 mus musculu
39	12	54.5	12	13	P82085	P82085 limnodynast
40	12	54.5	13	4	Q9UDE0	Q9ude0 homo sapien
41	12	54.5	13	4	Q96PI0	Q96pi0 homo sapien
42	12	54.5	13	5	Q9U5J2	Q9u5j2 trypanosoma
43	12	54.5	13	7	Q9TNQ8	Q9tnq8 homo sapien
44	12	54.5	13	13	P82848	P82848 rana pipien
45	12	54.5	14	2	P96350	P96350 legionella
46	12	54.5	14	4	Q8IWS6	Q8iws6 homo sapien
47	12	54.5	14	10	P82327	P82327 pisum sativ
48	12	54.5	14	12	Q8V1H7	Q8v1h7 hepatitis b
49	12	54.5	14	13	P82831	P82831 rana luteiv
50	12	54.5	14	13	P82832	P82832 rana luteiv
51	12	54.5	15	2	Q9X637	Q9x637 klebsiella
52	12	54.5	15	2	Q46013	Q46013 caulobacter
53	12	54.5	15	2	Q9X635	Q9x635 escherichia
54	12	54.5	15	4	Q9UQA5	Q9uqa5 homo sapien
55	12	54.5	15	4	Q9BXQ0	Q9bxq0 homo sapien
56	12	54.5	15	5	Q27266	Q27266 trypanosoma
57	12	54.5	15	6	Q8WNQ2	Q8wnq2 sus scrofa

ALIGNMENTS

```
RESULT 1
Q9UAR8
ID   Q9UAR8      PRELIMINARY;      PRT;    11 AA.
AC   Q9UAR8;
DT   01-MAY-2000 (TrEMBLrel. 13, Created)
DT   01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT   01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE   Sialokinin I preproprotein (Fragment).
OS   Aedes aegypti (Yellowfever mosquito).
OC   Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Aedes.
OX   NCBI_TaxID=7159;
RN   [1]
RP   SEQUENCE FROM N.A.
RC   STRAIN=Rockefeller/Red; TISSUE=Salivary gland;
RX   MEDLINE=20099025; PubMed=10620041;
RA   Beerntsen B.T., Champagne D.E., Coleman J.L., Campos Y.A., James A.A.;
RT   "Characterization of the Sialokinin I gene encoding the salivary
RT   vasodilator of the yellow fever mosquito, Aedes aegypti.";
RL   Insect Mol. Biol. 8:459-467(1999).
DR   EMBL; AF108100; AAD16884.1; -.
DR   GO; GO:0007268; P:synaptic transmission; IEA.
DR   GO; GO:0007217; P:tachykinin signaling pathway; IEA.
DR   InterPro; IPR002040; Tachy_Neurokinin.
DR   PROSITE; PS00267; TACHYKININ; 1.
FT   NON_TER       1      1
SQ   SEQUENCE   11 AA;  1203 MW;  8BADC77C6B59C33A CRC64;

  Query Match             90.9%;  Score 20;  DB 5;  Length 11;
  Best Local Similarity   80.0%;  Pred. No. 96;
  Matches    4;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 FXGLM 5
              | |||
Db          6 FYGLM 10


Search completed: April  7, 2004, 09:26:16
Job time : 63 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: April 7, 2004, 09:15:16 ; Search time 11 Seconds
(without alignments)
23.668 Million cell updates/sec

Title: US-10-030-388A-1
Perfect score: 22
Sequence: 1 FXGLM 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 801

Minimum DB seq length: 0
Maximum DB seq length: 15

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : SwissProt_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	21	95.5	13	1	CP1_APLCA	Q10998 aplysia cal
2	20	90.9	10	1	TKN1_SCYCA	P08608 scyliorhinu
3	20	90.9	10	1	TKNB_CHICK	P19851 gallus gall
4	20	90.9	10	1	TKNB_ONCMY	P28500 oncorhynchu
5	20	90.9	10	1	TKNB_RANCA	P22689 rana catesb
6	20	90.9	10	1	TKNB_RANRI	P29135 rana ridibu
7	20	90.9	10	1	TKNC_RANCA	P22690 rana catesb
8	20	90.9	10	1	TKNK_PIG	P01292 sus scrofa
9	20	90.9	10	1	TKN_PHYBI	P08610 phyllomedus
10	20	90.9	10	1	TKS1_AEDAE	P42634 aedes aegyp
11	20	90.9	10	1	TKS2_AEDAE	P42635 aedes aegyp
12	20	90.9	11	1	TKN1_PSEGU	P42986 pseudophryn
13	20	90.9	11	1	TKN1_UPEIN	P82026 uperoleia i
14	20	90.9	11	1	TKN1_UPERU	P08612 uperoleia r
15	20	90.9	11	1	TKN2_PSEGU	P42987 pseudophryn
16	20	90.9	11	1	TKN2_UPERU	P08616 uperoleia r
17	20	90.9	11	1	TKN3_PSEGU	P42988 pseudophryn

18	20	90.9	11	1	TKN4_PSEGU	P42989 pseudophryn
19	20	90.9	11	1	TKN5_PSEGU	P42990 pseudophryn
20	20	90.9	11	1	TKNA_CHICK	P19850 gallus gall
21	20	90.9	11	1	TKNA_GADMO	P28498 gadus morhu
22	20	90.9	11	1	TKNA_HORSE	P01290 equus cabal
23	20	90.9	11	1	TKNA_ONCMY	P28499 oncorhynchu
24	20	90.9	11	1	TKNA_RANCA	P22688 rana catesb
25	20	90.9	11	1	TKNA_RANRI	P29207 rana ridibu
26	20	90.9	11	1	TKNA_SCYCA	P41333 scyliorhinu
27	20	90.9	11	1	TKN_ELEMO	P01293 eledone mos
28	20	90.9	11	1	TKN_PHYFU	P08615 physalaemus
29	20	90.9	12	1	TKN1_KASMA	P08613 kassina mac
30	20	90.9	12	1	TKN_KASSE	P08611 kassina sen
31	20	90.9	14	1	TKNM_RANMA	P40951 rana margar
32	18	81.8	12	1	TKN2_KASMA	P08614 kassina mac
33	14	63.6	15	1	ATP2_PINPS	P81663 pinus pinas
34	13	59.1	9	1	TRP4_LEUMA	P81736 leucophaea
35	13	59.1	10	1	TRP6_LEUMA	P81738 leucophaea
36	13	59.1	10	1	TRP7_LEUMA	P81739 leucophaea
37	13	59.1	10	1	TRP8_LEUMA	P81740 leucophaea
38	13	59.1	10	1	TRP9_LEUMA	P81741 leucophaea
39	13	59.1	12	1	PA2B_VIPBO	P31859 vipera beru
40	13	59.1	15	1	R13A_SPIOL	P82454 spinacia ol
41	12	54.5	9	1	CCAP_CARMA	P38556 carcinus ma
42	12	54.5	9	1	FIBB_MACFU	P19345 macaca fusc
43	12	54.5	9	1	RE42_LITRU	P82075 litoria rub
44	12	54.5	9	1	TKC1_CALVO	P41517 calliphora
45	12	54.5	9	1	TKL1_LOCMI	P16223 locusta mig
46	12	54.5	10	1	CAER_LITXA	P56264 litoria xan
47	12	54.5	10	1	CU30_LOCMI	P11735 locusta mig
48	12	54.5	10	1	TKL2_LOCMI	P16224 locusta mig
49	12	54.5	10	1	TKL3_LOCMI	P30249 locusta mig
50	12	54.5	10	1	TKL4_LOCMI	P30250 locusta mig
51	12	54.5	10	1	TRP5_LEUMA	P81737 leucophaea
52	12	54.5	11	1	RE41_LITRU	P82074 litoria rub
53	12	54.5	11	1	TKC2_CALVO	P41518 calliphora
54	12	54.5	12	1	CD11_LITXA	P56245 litoria xan
55	12	54.5	12	1	CD14_LITXA	P56246 litoria xan
56	12	54.5	12	1	FRE1_LITIN	P82021 litoria inf
57	12	54.5	13	1	CD71_LITEW	P82051 litoria ewi
58	12	54.5	13	1	CHEP_PARID	P42718 parapolybia
59	12	54.5	13	1	CRBL_ICASP	P17237 icaria sp.
60	12	54.5	13	1	CRBL_VESAN	P17233 vespa anali
61	12	54.5	13	1	CRBL_VESLE	P17235 vespula lew
62	12	54.5	13	1	CRBL_VESMA	P17232 vespa manda
63	12	54.5	13	1	CRBL_VESTR	P17231 vespa tropi
64	12	54.5	13	1	CRBL_VESXA	P17234 vespa xanth
65	12	54.5	13	1	HPB9_RANES	P32416 rana escule
66	12	54.5	13	1	TEMC_RANTE	P56918 rana tempor
67	12	54.5	14	1	CRBL_VESOR	P17236 vespa orien
68	12	54.5	15	1	CDN2_LITGI	P56247 litoria gil
69	12	54.5	15	1	CDN4_LITCE	P82076 litoria cae
70	12	54.5	15	1	CDN5_LITCE	P82077 litoria cae
71	12	54.5	15	1	CDN6_LITCE	P82078 litoria cae
72	12	54.5	15	1	FRE2_LITIN	P82022 litoria inf
73	12	54.5	15	1	LEC1_PSOSC	P22582 psophocarpu
74	12	54.5	15	1	URE1_MORMO	P17337 morganella

ALIGNMENTS

```
RESULT 1
CP1_APLCA
ID   CP1_APLCA      STANDARD;      PRT;     13 AA.
AC   Q10998;
DT   01-OCT-1996 (Rel. 34, Created)
DT   01-OCT-1996 (Rel. 34, Last sequence update)
DT   01-OCT-1996 (Rel. 34, Last annotation update)
DE   Cerebral peptide 1 (CP1).
OS   Aplysia californica (California sea hare).
OC   Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
OC   Apogastropoda; Heterobranchia; Euthyneura; Opisthobranchia; Anaspidea;
OC   Aplysioidea; Aplysiidae; Aplysia.
OX   NCBI_TaxID=6500;
RN   [1]
RP   SEQUENCE.
RC   TISSUE=Ganglion;
RX   MEDLINE=97001771; PubMed=8844763;
RA   Phares G.A., Lloyd P.E.;
RT   "Purification, primary structure, and neuronal localization of
RT   cerebral peptide 1 from Aplysia.";
RL   Peptides 17:753-761(1996).
CC   -!- FUNCTION: May function as a peptide transmitter.
CC   -!- TISSUE SPECIFICITY: Found predominantly in the cerebral and pedal
CC       ganglia.
SQ   SEQUENCE   13 AA;  1314 MW;  9DBC3CE82C667B05 CRC64;

  Query Match             95.5%;  Score 21;  DB 1;  Length 13;
  Best Local Similarity   80.0%;  Pred. No. 8.8;
  Matches    4;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 FXGLM 5
              | |||
Db          1 FSGLM 5


Search completed: April  7, 2004, 09:25:09
Job time : 20 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: April 7, 2004, 09:23:37 ; Search time 21 Seconds
(without alignments)
22.903 Million cell updates/sec

Title: US-10-030-388A-1
Perfect score: 22
Sequence: 1 FXGLM 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 2522

Minimum DB seq length: 0
Maximum DB seq length: 15

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : PIR_78:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	20	90.9	10	1	SPPGNK	neuromedin K - pig
2	20	90.9	10	2	JN0024	neurokinin A - chi
3	20	90.9	10	2	A49581	sialokinin I - yel
4	20	90.9	10	2	B49581	sialokinin II - ye
5	20	90.9	10	2	A24867	scyliorhinin I - s
6	20	90.9	10	2	S23307	neurokinin A - rai
7	20	90.9	10	2	S23186	neurokinin A - Atl
8	20	90.9	10	2	S07202	phyllomedulin - tw
9	20	90.9	10	2	B61033	ranatachykinin B -
10	20	90.9	10	2	C61033	ranatachykinin C -
11	20	90.9	10	2	S27178	neurokinin A-relat
12	20	90.9	11	1	SPHO	substance P - hors
13	20	90.9	11	1	EOOCC	eledoisin - curled

14	20	90.9	11	1	A60654	substance P - guin
15	20	90.9	11	1	EOOC	eledoisin - musky
16	20	90.9	11	2	JN0023	substance P - chic
17	20	90.9	11	2	D60409	kassinin-like pept
18	20	90.9	11	2	F60409	substance P-like p
19	20	90.9	11	2	E60409	substance P-like p
20	20	90.9	11	2	S23308	substance P - rain
21	20	90.9	11	2	S23306	substance P - Atla
22	20	90.9	11	2	B60409	kassinin-like pept
23	20	90.9	11	2	C60409	kassinin-like pept
24	20	90.9	11	2	S07203	uperolein - frog (
25	20	90.9	11	2	S07201	physalaemin - frog
26	20	90.9	11	2	A61033	ranatachykinin A -
27	20	90.9	11	2	S33300	probable substance
28	20	90.9	12	2	S10059	tachykinin - Afric
29	20	90.9	12	2	S07206	kassinin - Senegal
30	18	81.8	12	2	S07436	tachykinin - Afric
31	15	68.2	10	2	S19296	16K protein - poul
32	15	68.2	14	2	PA0096	pyruvate decarboxy
33	15	68.2	15	2	H56978	collagen alpha 1(X
34	14	63.6	11	2	PT0249	Ig heavy chain CRD
35	14	63.6	12	2	B46662	collagen alpha 2(V
36	14	63.6	15	2	S36893	ribosomal protein
37	13	59.1	5	2	A61445	Met-enkephalin - b
38	13	59.1	7	2	A60224	Met-enkephalin-Arg
39	13	59.1	9	2	PT0225	Ig heavy chain CDR
40	13	59.1	9	2	PD0027	pev-tachykinin - p
41	13	59.1	13	2	A32734	enkephalin precurs
42	13	59.1	15	2	A28497	neurotensin-relate
43	12	54.5	8	2	S13661	polygalacturonase
44	12	54.5	9	2	A61357	phyllocaerulein -
45	12	54.5	9	2	C24180	fibrinogen beta ch
46	12	54.5	9	2	A26363	cardioactive pepti
47	12	54.5	9	2	S39766	cardioactive pepti
48	12	54.5	9	2	S27233	cardioactive pepti
49	12	54.5	9	2	S10784	enamelin i - bovin
50	12	54.5	9	2	PH0942	T-cell receptor be
51	12	54.5	9	2	S39767	cardioactive pepti
52	12	54.5	10	1	ECLQ1M	tachykinin I - mig
53	12	54.5	10	1	ECLQ3M	tachykinin III - m
54	12	54.5	10	1	ECLQ4M	tachykinin IV - mi
55	12	54.5	10	2	A61337	caerulein - frog (
56	12	54.5	10	2	S68033	cytochrome P450 1A
57	12	54.5	10	2	A59173	nuclease Bh1 (EC 3
58	12	54.5	11	1	ECLQ2M	tachykinin II - mi
59	12	54.5	11	2	A35594	buccalin - Califor
60	12	54.5	12	2	S26558	T-cell receptor be
61	12	54.5	12	2	PS0213	28K protein 4412 -
62	12	54.5	12	2	S74144	aggrecan - bovine
63	12	54.5	12	2	PH1635	Ig H chain V-D-J r
64	12	54.5	12	2	S39762	cytochrome P450 UT
65	12	54.5	12	2	S23168	Z protein - guinea
66	12	54.5	13	2	S36874	cytochrome P450 CM
67	12	54.5	13	2	S09019	hemolytic protein
68	12	54.5	13	2	B56864	dipeptidyl-peptida
69	12	54.5	14	2	JN0390	histamine-releasin
70	12	54.5	14	2	S50900	chlorophyll a/b-bi

ALIGNMENTS

RESULT 1
SPPGNK
neuromedin K - pig
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 19-Feb-1984 #sequence_revision 19-Feb-1984 #text_change 23-Aug-1996
C;Accession: A01560
R;Kangawa, K.; Minamino, N.; Fukuda, A.; Matsuo, H.
Biochem. Biophys. Res. Commun. 114, 533-540, 1983
A;Title: Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord.
A;Reference number: A01560; MUID:83282812; PMID:6576785
A;Accession: A01560
A;Molecule type: protein
A;Residues: 1-10 <KAN>
A;Note: the structure of the peptide was confirmed by synthesis
C;Comment: The biological source of this peptide is spinal cord. It stimulates smooth muscle contraction in mammalian assay systems, in a manner similar to that of substance P.
C;Superfamily: neurokinin B precursor
C;Keywords: amidated carboxyl end; hormone; spinal cord
F;10/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 90.9%; Score 20; DB 1; Length 10;
Best Local Similarity 80.0%; Pred. No. 25;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 FXGLM 5
| |||
Db 6 FVGLM 10

RESULT 2
JN0024
neurokinin A - chicken
C;Species: Gallus gallus (chicken)
C;Date: 07-Sep-1990 #sequence_revision 07-Sep-1990 #text_change 18-Aug-2000
C;Accession: JN0024
R;Conlon, J.M.; Katsoulis, S.; Schmidt, W.E.; Thim, L.
Regul. Pept. 20, 171-180, 1988
A;Title: [Arg3]substance P and neurokinin A from chicken small intestine.
A;Reference number: JN0023; MUID:88204263; PMID:2452461
A;Accession: JN0024
A;Molecule type: protein
A;Residues: 1-10 <CON>
C;Superfamily: substance P precursor
C;Keywords: amidated carboxyl end; neuropeptide; tachykinin
F;10/Modified site: amidated carboxyl end (Met) #status predicted

Query Match 90.9%; Score 20; DB 2; Length 10;
Best Local Similarity 80.0%; Pred. No. 25;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 FXGLM 5

| |||
Db 6 FVGLM 10

Search completed: April 7, 2004, 09:27:06
Job time : 26 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: April 7, 2004, 09:26:22 ; Search time 40 Seconds
(without alignments)
32.829 Million cell updates/sec

Title: US-10-030-388A-1
Perfect score: 22
Sequence: 1 FXGLM 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1071772 seqs, 262633353 residues

Total number of hits satisfying chosen parameters: 173463

Minimum DB seq length: 0
Maximum DB seq length: 15

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description

1	21	95.5	12	14	US-10-172-425B-16	Sequence 16, Appl
2	20	90.9	5	14	US-10-230-133-4	Sequence 4, Appli
3	20	90.9	5	14	US-10-053-669-1	Sequence 1, Appli
4	20	90.9	5	14	US-10-053-669-4	Sequence 4, Appli
5	20	90.9	6	14	US-10-168-789A-38	Sequence 38, Appl
6	20	90.9	7	14	US-10-036-542-110	Sequence 110, App
7	20	90.9	7	14	US-10-036-542-111	Sequence 111, App
8	20	90.9	7	14	US-10-168-789A-37	Sequence 37, Appl
9	20	90.9	8	9	US-09-910-552-36	Sequence 36, Appl
10	20	90.9	8	14	US-10-168-789A-36	Sequence 36, Appl
11	20	90.9	9	14	US-10-036-542-112	Sequence 112, App
12	20	90.9	9	14	US-10-168-789A-35	Sequence 35, Appl
13	20	90.9	10	9	US-09-853-161-110	Sequence 110, App
14	20	90.9	10	9	US-09-852-659A-110	Sequence 110, App
15	20	90.9	10	9	US-09-852-797-110	Sequence 110, App
16	20	90.9	10	10	US-09-988-792-11	Sequence 11, Appl
17	20	90.9	10	12	US-10-445-400-1	Sequence 1, Appli
18	20	90.9	10	12	US-10-445-400-2	Sequence 2, Appli
19	20	90.9	10	14	US-10-197-954-98	Sequence 98, Appl
20	20	90.9	10	14	US-10-197-954-99	Sequence 99, Appl
21	20	90.9	10	14	US-10-168-789A-34	Sequence 34, Appl
22	20	90.9	10	14	US-10-267-918-1	Sequence 1, Appli
23	20	90.9	10	14	US-10-267-918-2	Sequence 2, Appli
24	20	90.9	10	15	US-10-360-101-91	Sequence 91, Appl
25	20	90.9	11	9	US-09-935-682-64	Sequence 64, Appl
26	20	90.9	11	10	US-09-988-792-1	Sequence 1, Appli
27	20	90.9	11	10	US-09-988-792-6	Sequence 6, Appli
28	20	90.9	11	10	US-09-988-792-7	Sequence 7, Appli
29	20	90.9	11	10	US-09-988-792-8	Sequence 8, Appli
30	20	90.9	11	10	US-09-988-792-9	Sequence 9, Appli
31	20	90.9	11	10	US-09-988-792-10	Sequence 10, Appl
32	20	90.9	11	12	US-09-841-091B-26	Sequence 26, Appl
33	20	90.9	11	13	US-10-002-593-4	Sequence 4, Appli
34	20	90.9	11	14	US-10-230-133-1	Sequence 1, Appli
35	20	90.9	11	14	US-10-053-669-3	Sequence 3, Appli
36	20	90.9	11	14	US-10-211-994-3	Sequence 3, Appli
37	20	90.9	11	14	US-10-114-823B-24	Sequence 24, Appl
38	20	90.9	11	14	US-10-197-954-48	Sequence 48, Appl
39	20	90.9	11	14	US-10-197-954-117	Sequence 117, App
40	20	90.9	11	14	US-10-197-954-130	Sequence 130, App
41	20	90.9	11	14	US-10-197-954-138	Sequence 138, App
42	20	90.9	11	14	US-10-251-703-25	Sequence 25, Appl
43	20	90.9	11	14	US-10-168-789A-17	Sequence 17, Appl
44	20	90.9	11	14	US-10-423-714-4	Sequence 4, Appli
45	20	90.9	11	15	US-10-289-009-24	Sequence 24, Appl
46	20	90.9	11	15	US-10-289-009-25	Sequence 25, Appl
47	20	90.9	11	15	US-10-289-009-26	Sequence 26, Appl
48	20	90.9	12	9	US-09-922-093-2	Sequence 2, Appli
49	20	90.9	12	9	US-09-922-093-5	Sequence 5, Appli
50	20	90.9	12	9	US-09-922-093-8	Sequence 8, Appli
51	20	90.9	12	9	US-09-938-112-2	Sequence 2, Appli
52	20	90.9	12	9	US-09-938-112-5	Sequence 5, Appli
53	20	90.9	12	9	US-09-938-112-8	Sequence 8, Appli
54	20	90.9	12	14	US-10-082-691-2	Sequence 2, Appli
55	20	90.9	12	14	US-10-082-691-5	Sequence 5, Appli
56	20	90.9	12	14	US-10-082-691-8	Sequence 8, Appli

57	20	90.9	12	14	US-10-050-200-55	Sequence 55, Appl
58	20	90.9	12	15	US-10-394-511-41	Sequence 41, Appl
59	20	90.9	13	9	US-09-922-093-3	Sequence 3, Appli
60	20	90.9	13	9	US-09-922-093-6	Sequence 6, Appli
61	20	90.9	13	9	US-09-922-093-9	Sequence 9, Appli
62	20	90.9	13	9	US-09-938-112-3	Sequence 3, Appli
63	20	90.9	13	9	US-09-938-112-6	Sequence 6, Appli
64	20	90.9	13	9	US-09-938-112-9	Sequence 9, Appli
65	20	90.9	13	14	US-10-082-691-3	Sequence 3, Appli
66	20	90.9	13	14	US-10-082-691-6	Sequence 6, Appli
67	20	90.9	13	14	US-10-082-691-9	Sequence 9, Appli
68	20	90.9	14	9	US-09-922-093-4	Sequence 4, Appli
69	20	90.9	14	9	US-09-922-093-7	Sequence 7, Appli
70	20	90.9	14	9	US-09-922-093-10	Sequence 10, Appl
71	20	90.9	14	9	US-09-938-112-4	Sequence 4, Appli
72	20	90.9	14	9	US-09-938-112-7	Sequence 7, Appli
73	20	90.9	14	9	US-09-938-112-10	Sequence 10, Appl
74	20	90.9	14	12	US-10-415-024-6	Sequence 6, Appli
75	20	90.9	14	14	US-10-131-543-6	Sequence 6, Appli
76	20	90.9	14	14	US-10-131-546-6	Sequence 6, Appli
77	20	90.9	14	14	US-10-131-346-6	Sequence 6, Appli
78	20	90.9	14	14	US-10-082-691-4	Sequence 4, Appli
79	20	90.9	14	14	US-10-082-691-7	Sequence 7, Appli
80	20	90.9	14	14	US-10-082-691-10	Sequence 10, Appl
81	20	90.9	15	9	US-09-853-161-109	Sequence 109, App
82	20	90.9	15	9	US-09-852-659A-109	Sequence 109, App
83	20	90.9	15	9	US-09-852-797-109	Sequence 109, App
84	19	86.4	14	9	US-09-838-050-10	Sequence 10, Appl
85	19	86.4	14	9	US-09-854-173A-10	Sequence 10, Appl
86	17	77.3	5	14	US-10-168-789A-32	Sequence 32, Appl
87	17	77.3	5	14	US-10-168-789A-39	Sequence 39, Appl
88	17	77.3	9	9	US-09-748-451-20	Sequence 20, Appl
89	17	77.3	9	15	US-10-285-394-127	Sequence 127, App
90	17	77.3	10	14	US-10-057-789-123	Sequence 123, App
91	17	77.3	10	14	US-10-212-628-123	Sequence 123, App
92	17	77.3	10	14	US-10-168-789A-26	Sequence 26, Appl
93	17	77.3	10	14	US-10-168-789A-27	Sequence 27, Appl
94	17	77.3	11	9	US-09-966-871-20	Sequence 20, Appl
95	17	77.3	11	12	US-10-458-860-20	Sequence 20, Appl
96	17	77.3	11	13	US-10-039-645-20	Sequence 20, Appl
97	17	77.3	11	14	US-10-139-084-20	Sequence 20, Appl
98	17	77.3	11	14	US-10-168-789A-25	Sequence 25, Appl
99	17	77.3	12	12	US-10-351-891-114	Sequence 114, App
100	17	77.3	12	14	US-10-168-789A-24	Sequence 24, Appl
101	17	77.3	13	14	US-10-168-789A-23	Sequence 23, Appl
102	17	77.3	14	14	US-10-168-789A-22	Sequence 22, Appl
103	17	77.3	15	10	US-09-563-222-139	Sequence 139, App
104	17	77.3	15	14	US-10-168-789A-28	Sequence 28, Appl
105	16	72.7	6	9	US-09-732-384-5	Sequence 5, Appli
106	16	72.7	6	13	US-10-008-355-24	Sequence 24, Appl
107	16	72.7	7	14	US-10-286-457-483	Sequence 483, App
108	16	72.7	8	14	US-10-194-441A-24	Sequence 24, Appl
109	16	72.7	9	9	US-09-894-018-299	Sequence 299, App
110	16	72.7	9	15	US-10-371-069-162	Sequence 162, App
111	16	72.7	9	15	US-10-371-645-162	Sequence 162, App
112	16	72.7	9	15	US-10-371-260-162	Sequence 162, App
113	16	72.7	10	9	US-09-848-967-31	Sequence 31, Appl

ALIGNMENTS

RESULT 1
US-10-172-425B-16
; Sequence 16, Application US/10172425B
; Publication No. US20030147908A1
; GENERAL INFORMATION:
; APPLICANT: Kaempfer, Raymond
; APPLICANT: Arad, Gila
; TITLE OF INVENTION: BROAD SPECTRUM ANTAGONISTS AND VACCINES
; TITLE OF INVENTION: DIRECTED AGAINST PYROGENIC EXOTOXINS
; FILE REFERENCE: A31967-PCT-USA-A-A 066031.0164
; CURRENT APPLICATION NUMBER: US/10/172,425B
; CURRENT FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: 09/150,947
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: PCT/IL97/00438
; PRIOR FILING DATE: 1997-12-30
; PRIOR APPLICATION NUMBER: ISRAEL 119938
; PRIOR FILING DATE: 1996-12-30
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 12
; TYPE: PRT
; ORGANISM: Staphylococcus aureus
US-10-172-425B-16

Query Match 95.5%; Score 21; DB 14; Length 12;
Best Local Similarity 80.0%; Pred. No. 56;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 FXGLM 5
              | |||
Db          5 FTGLM 9
```

RESULT 2
US-10-230-133-4
; Sequence 4, Application US/10230133
; Publication No. US20030040625A1
; GENERAL INFORMATION:
; APPLICANT: Wells, Ibert
; TITLE OF INVENTION: Antagonists of the magnesium binding defect as therapy agents and
; TITLE OF INVENTION: methods for treatment of abnormal physiological states
; FILE REFERENCE: 2892-106
; CURRENT APPLICATION NUMBER: US/10/230,133
; CURRENT FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 09/635,266
; PRIOR FILING DATE: 2000-08-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 5
; TYPE: PRT

; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD_RES
; LOCATION: (5)..(5)
; OTHER INFORMATION: AMIDATION
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (2)..(2)
; OTHER INFORMATION: "X" may be either F or V.
US-10-230-133-4

  Query Match   90.9%; Score 20; DB 14; Length 5;
  Best Local Similarity   100.0%; Pred. No. 9.7e+05;
  Matches   5; Conservative   0; Mismatches   0; Indels   0; Gaps   0;

Qy   1 FXGLM 5
              |||||
Db   1 FXGLM 5

Search completed: April 7, 2004, 09:31:30
Job time : 44 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: April 7, 2004, 09:22:07 ; Search time 22 Seconds
(without alignments)
11.733 Million cell updates/sec

Title: US-10-030-388A-1
Perfect score: 22
Sequence: 1 FXGLM 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 146418

Minimum DB seq length: 0
Maximum DB seq length: 15

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	20	90.9	5	1	US-07-753-909B-3	Sequence 3, Appli
2	20	90.9	5	1	US-07-934-553-2	Sequence 2, Appli
3	20	90.9	5	1	US-08-269-288-1	Sequence 1, Appli
4	20	90.9	5	1	US-08-225-474-2	Sequence 2, Appli
5	20	90.9	5	1	US-08-391-910-1	Sequence 1, Appli
6	20	90.9	5	1	US-08-418-994-1	Sequence 1, Appli
7	20	90.9	5	1	US-08-391-814-1	Sequence 1, Appli
8	20	90.9	5	1	US-08-441-591-61	Sequence 61, Appl
9	20	90.9	5	1	US-08-303-362A-61	Sequence 61, Appl
10	20	90.9	5	1	US-08-462-415-1	Sequence 1, Appli
11	20	90.9	5	1	US-08-463-874-1	Sequence 1, Appli

12	20	90.9	5	1	US-08-444-135-1	Sequence 1, Appli
13	20	90.9	5	1	US-08-318-391-1	Sequence 1, Appli
14	20	90.9	5	2	US-07-737-371E-6	Sequence 6, Appli
15	20	90.9	5	3	US-08-257-966-1	Sequence 1, Appli
16	20	90.9	5	4	US-09-265-690C-1	Sequence 1, Appli
17	20	90.9	5	4	US-09-265-690C-4	Sequence 4, Appli
18	20	90.9	5	4	US-08-153-847-1	Sequence 1, Appli
19	20	90.9	5	4	US-09-635-266-4	Sequence 4, Appli
20	20	90.9	5	4	US-10-230-133-4	Sequence 4, Appli
21	20	90.9	5	5	PCT-US95-05600-78	Sequence 78, Appl
22	20	90.9	6	1	US-07-934-553-3	Sequence 3, Appli
23	20	90.9	6	1	US-08-225-474-3	Sequence 3, Appli
24	20	90.9	6	1	US-08-430-238-15	Sequence 15, Appl
25	20	90.9	6	2	US-07-737-371E-5	Sequence 5, Appli
26	20	90.9	6	2	US-07-737-371E-52	Sequence 52, Appl
27	20	90.9	6	3	US-09-317-125-5	Sequence 5, Appli
28	20	90.9	7	1	US-07-712-828B-7	Sequence 7, Appli
29	20	90.9	7	2	US-07-737-371E-8	Sequence 8, Appli
30	20	90.9	7	2	US-07-737-371E-51	Sequence 51, Appl
31	20	90.9	8	2	US-07-737-371E-10	Sequence 10, Appl
32	20	90.9	8	2	US-07-737-371E-56	Sequence 56, Appl
33	20	90.9	8	3	US-08-925-002-36	Sequence 36, Appl
34	20	90.9	8	4	US-09-910-552-36	Sequence 36, Appl
35	20	90.9	9	2	US-07-737-371E-60	Sequence 60, Appl
36	20	90.9	10	1	US-07-899-205-2	Sequence 2, Appli
37	20	90.9	10	1	US-07-899-205-3	Sequence 3, Appli
38	20	90.9	10	1	US-08-088-322-6	Sequence 6, Appli
39	20	90.9	10	1	US-08-193-393-1	Sequence 1, Appli
40	20	90.9	10	1	US-08-184-935-9	Sequence 9, Appli
41	20	90.9	10	1	US-08-184-935-10	Sequence 10, Appl
42	20	90.9	10	1	US-08-269-288-3	Sequence 3, Appli
43	20	90.9	10	1	US-08-269-288-4	Sequence 4, Appli
44	20	90.9	10	1	US-08-338-484-2	Sequence 2, Appli
45	20	90.9	10	1	US-08-338-484-3	Sequence 3, Appli
46	20	90.9	10	1	US-08-175-432-2	Sequence 2, Appli
47	20	90.9	10	1	US-08-175-432-3	Sequence 3, Appli
48	20	90.9	10	1	US-08-462-413-3	Sequence 3, Appli
49	20	90.9	10	1	US-08-462-413-4	Sequence 4, Appli
50	20	90.9	10	1	US-08-391-910-3	Sequence 3, Appli
51	20	90.9	10	1	US-08-391-910-4	Sequence 4, Appli
52	20	90.9	10	1	US-08-418-994-3	Sequence 3, Appli
53	20	90.9	10	1	US-08-418-994-4	Sequence 4, Appli
54	20	90.9	10	1	US-08-391-814-3	Sequence 3, Appli
55	20	90.9	10	1	US-08-391-814-4	Sequence 4, Appli
56	20	90.9	10	1	US-08-167-870-2	Sequence 2, Appli
57	20	90.9	10	1	US-08-167-870-3	Sequence 3, Appli
58	20	90.9	10	1	US-08-437-820-6	Sequence 6, Appli
59	20	90.9	10	1	US-08-462-415-3	Sequence 3, Appli
60	20	90.9	10	1	US-08-462-415-4	Sequence 4, Appli
61	20	90.9	10	1	US-08-463-874-3	Sequence 3, Appli
62	20	90.9	10	1	US-08-463-874-4	Sequence 4, Appli
63	20	90.9	10	1	US-08-318-391-3	Sequence 3, Appli
64	20	90.9	10	1	US-08-318-391-4	Sequence 4, Appli
65	20	90.9	10	2	US-08-496-118-2	Sequence 2, Appli
66	20	90.9	10	2	US-08-496-118-3	Sequence 3, Appli
67	20	90.9	10	2	US-07-737-371E-9	Sequence 9, Appli
68	20	90.9	10	2	US-07-737-371E-43	Sequence 43, Appl

69	20	90.9	10	2	US-07-737-371E-74	Sequence 74, Appl
70	20	90.9	10	2	US-07-737-371E-75	Sequence 75, Appl
71	20	90.9	10	3	US-08-257-966-3	Sequence 3, Appli
72	20	90.9	10	3	US-08-257-966-4	Sequence 4, Appli
73	20	90.9	10	3	US-09-168-548-2	Sequence 2, Appli
74	20	90.9	10	4	US-09-174-216-8	Sequence 8, Appli
75	20	90.9	10	4	US-08-153-847-3	Sequence 3, Appli
76	20	90.9	10	4	US-08-153-847-4	Sequence 4, Appli
77	20	90.9	10	4	US-09-152-060-110	Sequence 110, App
78	20	90.9	10	6	5169865-11	Patent No. 5169865
79	20	90.9	11	1	US-07-899-205-1	Sequence 1, Appli
80	20	90.9	11	1	US-07-753-909B-2	Sequence 2, Appli
81	20	90.9	11	1	US-07-934-553-1	Sequence 1, Appli
82	20	90.9	11	1	US-08-184-935-12	Sequence 12, Appl
83	20	90.9	11	1	US-08-269-288-2	Sequence 2, Appli
84	20	90.9	11	1	US-08-338-484-1	Sequence 1, Appli
85	20	90.9	11	1	US-08-175-432-1	Sequence 1, Appli
86	20	90.9	11	1	US-08-462-413-2	Sequence 2, Appli
87	20	90.9	11	1	US-08-225-474-1	Sequence 1, Appli
88	20	90.9	11	1	US-08-391-910-2	Sequence 2, Appli
89	20	90.9	11	1	US-08-418-994-2	Sequence 2, Appli
90	20	90.9	11	1	US-08-480-505-3	Sequence 3, Appli
91	20	90.9	11	1	US-08-391-814-2	Sequence 2, Appli
92	20	90.9	11	1	US-08-167-870-1	Sequence 1, Appli
93	20	90.9	11	1	US-08-428-488-15	Sequence 15, Appl
94	20	90.9	11	1	US-08-428-488-16	Sequence 16, Appl
95	20	90.9	11	1	US-08-428-488-17	Sequence 17, Appl
96	20	90.9	11	1	US-08-255-272-6	Sequence 6, Appli
97	20	90.9	11	1	US-08-441-591-6	Sequence 6, Appli
98	20	90.9	11	1	US-08-303-362A-6	Sequence 6, Appli
99	20	90.9	11	1	US-08-462-859A-1	Sequence 1, Appli
100	20	90.9	11	1	US-08-123-659A-1	Sequence 1, Appli
101	20	90.9	11	1	US-08-462-415-2	Sequence 2, Appli
102	20	90.9	11	1	US-08-463-874-2	Sequence 2, Appli
103	20	90.9	11	1	US-08-464-247A-1	Sequence 1, Appli
104	20	90.9	11	1	US-08-464-248A-1	Sequence 1, Appli
105	20	90.9	11	1	US-08-444-135-2	Sequence 2, Appli
106	20	90.9	11	1	US-08-318-391-2	Sequence 2, Appli
107	20	90.9	11	2	US-08-796-598-7	Sequence 7, Appli
108	20	90.9	11	2	US-08-796-598-11	Sequence 11, Appl
109	20	90.9	11	2	US-08-496-118-1	Sequence 1, Appli
110	20	90.9	11	2	US-08-447-175A-7	Sequence 7, Appli
111	20	90.9	11	2	US-08-447-175A-11	Sequence 11, Appl
112	20	90.9	11	2	US-07-737-371E-15	Sequence 15, Appl
113	20	90.9	11	2	US-07-737-371E-16	Sequence 16, Appl
114	20	90.9	11	2	US-07-737-371E-18	Sequence 18, Appl
115	20	90.9	11	2	US-07-737-371E-19	Sequence 19, Appl
116	20	90.9	11	2	US-07-737-371E-25	Sequence 25, Appl
117	20	90.9	11	2	US-07-737-371E-26	Sequence 26, Appl
118	20	90.9	11	2	US-07-737-371E-35	Sequence 35, Appl
119	20	90.9	11	2	US-07-737-371E-36	Sequence 36, Appl
120	20	90.9	11	2	US-07-737-371E-37	Sequence 37, Appl
121	20	90.9	11	2	US-07-737-371E-38	Sequence 38, Appl
122	20	90.9	11	2	US-07-737-371E-73	Sequence 73, Appl
123	20	90.9	11	2	US-07-737-371E-77	Sequence 77, Appl
124	20	90.9	11	2	US-08-848-766A-1	Sequence 1, Appli
125	20	90.9	11	3	US-08-890-157A-4	Sequence 4, Appli

126	20	90.9	11	3	US-08-927-128-17	Sequence 17, Appl
127	20	90.9	11	3	US-08-257-966-2	Sequence 2, Appli
128	20	90.9	11	3	US-09-214-614-1	Sequence 1, Appli
129	20	90.9	11	4	US-09-265-690C-3	Sequence 3, Appli
130	20	90.9	11	4	US-08-153-847-2	Sequence 2, Appli
131	20	90.9	11	4	US-09-635-266-1	Sequence 1, Appli
132	20	90.9	11	4	US-09-570-022-1	Sequence 1, Appli
133	20	90.9	11	4	US-09-570-022-5	Sequence 5, Appli
134	20	90.9	11	4	US-09-570-022-6	Sequence 6, Appli
135	20	90.9	11	4	US-09-570-022-10	Sequence 10, Appl
136	20	90.9	11	4	US-10-002-593-4	Sequence 4, Appli
137	20	90.9	11	4	US-09-629-642A-1	Sequence 1, Appli
138	20	90.9	11	4	US-10-230-133-1	Sequence 1, Appli
139	20	90.9	11	5	PCT-US92-06532-1	Sequence 1, Appli
140	20	90.9	11	5	PCT-US95-05600-23	Sequence 23, Appl
141	20	90.9	11	6	5441935-1	Patent No. 5441935
142	20	90.9	12	1	US-08-428-488-18	Sequence 18, Appl
143	20	90.9	12	1	US-08-441-591-7	Sequence 7, Appli
144	20	90.9	12	1	US-08-303-362A-7	Sequence 7, Appli
145	20	90.9	12	2	US-08-796-598-10	Sequence 10, Appl
146	20	90.9	12	2	US-08-447-175A-10	Sequence 10, Appl
147	20	90.9	12	2	US-07-737-371E-76	Sequence 76, Appl
148	20	90.9	12	3	US-08-505-250-27	Sequence 27, Appl
149	20	90.9	12	3	US-08-505-250-53	Sequence 53, Appl
150	20	90.9	12	4	US-09-264-709A-16	Sequence 16, Appl
151	20	90.9	12	4	US-08-505-250-27	Sequence 27, Appl
152	20	90.9	12	4	US-08-505-250-53	Sequence 53, Appl
153	20	90.9	12	4	US-09-922-093-2	Sequence 2, Appli
154	20	90.9	12	4	US-09-922-093-5	Sequence 5, Appli
155	20	90.9	12	4	US-09-922-093-8	Sequence 8, Appli
156	20	90.9	12	4	US-09-403-752A-41	Sequence 41, Appl
157	20	90.9	12	4	US-09-763-669-1	Sequence 1, Appli
158	20	90.9	12	4	US-09-763-669-2	Sequence 2, Appli
159	20	90.9	12	4	US-09-625-098F-2	Sequence 2, Appli
160	20	90.9	12	4	US-09-625-098F-5	Sequence 5, Appli
161	20	90.9	12	4	US-09-625-098F-8	Sequence 8, Appli
162	20	90.9	12	5	PCT-US92-06532-4	Sequence 4, Appli
163	20	90.9	12	5	PCT-US95-05600-24	Sequence 24, Appl
164	20	90.9	13	1	US-07-712-828B-5	Sequence 5, Appli
165	20	90.9	13	2	US-07-737-371E-46	Sequence 46, Appl
166	20	90.9	13	4	US-09-922-093-3	Sequence 3, Appli
167	20	90.9	13	4	US-09-922-093-6	Sequence 6, Appli
168	20	90.9	13	4	US-09-922-093-9	Sequence 9, Appli
169	20	90.9	13	4	US-09-625-098F-3	Sequence 3, Appli
170	20	90.9	13	4	US-09-625-098F-6	Sequence 6, Appli
171	20	90.9	13	4	US-09-625-098F-9	Sequence 9, Appli
172	20	90.9	14	4	US-09-922-093-4	Sequence 4, Appli
173	20	90.9	14	4	US-09-922-093-7	Sequence 7, Appli
174	20	90.9	14	4	US-09-922-093-10	Sequence 10, Appl
175	20	90.9	14	4	US-09-625-098F-4	Sequence 4, Appli
176	20	90.9	14	4	US-09-625-098F-7	Sequence 7, Appli
177	20	90.9	14	4	US-09-625-098F-10	Sequence 10, Appl
178	20	90.9	15	4	US-09-152-060-109	Sequence 109, App
179	19	86.4	10	2	US-07-737-371E-42	Sequence 42, Appl
180	19	86.4	10	2	US-07-737-371E-44	Sequence 44, Appl
181	19	86.4	11	2	US-07-737-371E-33	Sequence 33, Appl
182	19	86.4	11	4	US-09-570-022-7	Sequence 7, Appli

183	19	86.4	11	4	US-09-570-022-8	Sequence 8, Appli
184	19	86.4	11	4	US-09-570-022-9	Sequence 9, Appli
185	19	86.4	14	3	US-08-869-285-10	Sequence 10, Appl
186	19	86.4	14	3	US-09-255-533-10	Sequence 10, Appl
187	17	77.3	5	2	US-07-737-371E-48	Sequence 48, Appl
188	17	77.3	6	3	US-08-987-743-13	Sequence 13, Appl
189	17	77.3	9	3	US-09-061-702-20	Sequence 20, Appl
190	17	77.3	10	1	US-08-299-285-21	Sequence 21, Appl
191	17	77.3	10	2	US-08-985-126-21	Sequence 21, Appl
192	17	77.3	10	4	US-09-358-020-21	Sequence 21, Appl
193	17	77.3	10	5	PCT-US95-11126-21	Sequence 21, Appl
194	17	77.3	11	2	US-07-737-371E-12	Sequence 12, Appl
195	17	77.3	14	1	US-07-908-317-17	Sequence 17, Appl
196	17	77.3	14	5	PCT-US93-06171-17	Sequence 17, Appl
197	17	77.3	15	5	PCT-US94-06655-4	Sequence 4, Appli
198	16	72.7	6	1	US-08-277-660A-3	Sequence 3, Appli
199	16	72.7	6	1	US-08-424-957-3	Sequence 3, Appli
200	16	72.7	6	3	US-09-035-686-3	Sequence 3, Appli
201	16	72.7	8	1	US-07-920-519-9	Sequence 9, Appli
202	16	72.7	8	1	US-08-086-410-6	Sequence 6, Appli
203	16	72.7	8	1	US-08-314-586-9	Sequence 9, Appli
204	16	72.7	8	3	US-08-444-818-431	Sequence 431, App
205	16	72.7	8	3	US-08-444-818-432	Sequence 432, App
206	16	72.7	9	3	US-08-159-339A-337	Sequence 337, App
207	16	72.7	9	3	US-08-159-339A-824	Sequence 824, App
208	16	72.7	9	4	US-09-311-784A-162	Sequence 162, App
209	16	72.7	10	1	US-08-277-660A-8	Sequence 8, Appli
210	16	72.7	10	1	US-08-424-957-12	Sequence 12, Appl
211	16	72.7	10	3	US-08-159-339A-854	Sequence 854, App
212	16	72.7	10	3	US-09-035-686-12	Sequence 12, Appl
213	16	72.7	11	4	US-09-462-951B-8	Sequence 8, Appli
214	16	72.7	12	2	US-08-764-640-128	Sequence 128, App
215	16	72.7	12	2	US-08-553-257A-25	Sequence 25, Appl
216	16	72.7	12	2	US-08-553-257A-27	Sequence 27, Appl
217	16	72.7	12	2	US-08-553-257A-28	Sequence 28, Appl
218	16	72.7	12	2	US-08-553-257A-29	Sequence 29, Appl
219	16	72.7	12	2	US-08-553-257A-30	Sequence 30, Appl
220	16	72.7	12	3	US-08-973-225-128	Sequence 128, App
221	16	72.7	12	3	US-09-244-298A-128	Sequence 128, App
222	16	72.7	12	3	US-09-516-704-128	Sequence 128, App
223	16	72.7	12	4	US-09-549-090-128	Sequence 128, App
224	16	72.7	12	4	US-09-832-230A-128	Sequence 128, App
225	16	72.7	12	4	US-09-441-992-25	Sequence 25, Appl
226	16	72.7	12	4	US-09-441-992-27	Sequence 27, Appl
227	16	72.7	12	4	US-09-441-992-28	Sequence 28, Appl
228	16	72.7	12	4	US-09-441-992-29	Sequence 29, Appl
229	16	72.7	12	4	US-09-441-992-30	Sequence 30, Appl
230	16	72.7	12	4	US-09-428-082B-50	Sequence 50, Appl
231	16	72.7	13	4	US-09-385-740B-14	Sequence 14, Appl
232	16	72.7	13	4	US-10-073-679-14	Sequence 14, Appl
233	16	72.7	13	4	US-10-009-999A-14	Sequence 14, Appl
234	16	72.7	14	3	US-09-335-098A-4	Sequence 4, Appli
235	16	72.7	14	4	US-09-385-740B-4	Sequence 4, Appli
236	16	72.7	14	4	US-10-073-679-4	Sequence 4, Appli
237	16	72.7	14	4	US-10-009-999A-4	Sequence 4, Appli
238	16	72.7	15	1	US-08-277-660A-5	Sequence 5, Appli
239	16	72.7	15	1	US-08-277-660A-6	Sequence 6, Appli

ALIGNMENTS

```
RESULT 1
US-07-753-909B-3
; Sequence 3, Application US/07753909B
; Patent No. 5304632
;  GENERAL INFORMATION:
;    APPLICANT:  Vaudry, Hubert
;    APPLICANT:  Conlon, Michael J.
;    TITLE OF INVENTION:  Neuropeptides of the Tachykinin Family
;    NUMBER OF SEQUENCES:  3
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Zarley, McKee, Thomte, Voorhees, and Sease
;      STREET:  801 Grand, Suite 3200
;      CITY:  Des Moines
;      STATE:  Iowa
;      COUNTRY:  United States
;      ZIP:  50309
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/753,909B
;      FILING DATE:  19910903
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  FR 9106759
;      FILING DATE:  04-JUN-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Sease, Edmund J.
;      REGISTRATION NUMBER:  24,741
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (515)-288-3667
;      TELEFAX:  (515)-288-1338
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  AMINO ACID
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  C-terminal
;    ORIGINAL SOURCE:
;      ORGANISM:  Rana ridibunda
;      DEVELOPMENTAL STAGE:  adult
;      TISSUE TYPE:  brain
US-07-753-909B-3

  Query Match             90.9%;  Score 20;  DB 1;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 3e+05;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 FXGLM 5
```

```
                |||||
Db          1 FXGLM 5


RESULT 2
US-07-934-553-2
; Sequence 2, Application US/07934553
; Patent No. 5314690
;  GENERAL INFORMATION:
;    APPLICANT:  PATTERSON, ROY
;    APPLICANT:  HARRIS, KATHLEEN E
;    TITLE OF INVENTION:  METHOD AND COMPOSITION FOR REDUCING IgE
;    TITLE OF INVENTION:  ANTIBODIES TO SPECIFIC ALLERGENS
;    NUMBER OF SEQUENCES:  5
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  TILTON, FALLON, LUNGMUS & CHESTNUT
;      STREET:  100 SOUTH WACKER DRIVE
;      CITY:  CHICAGO
;      STATE:  ILLINOIS
;      COUNTRY:  USA
;      ZIP:  60606-4002
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/934,553
;      FILING DATE:  19920821
;      CLASSIFICATION:  424
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/705,071
;      FILING DATE:  24-MAY-1991
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  FENTRESS, SUSAN B
;      REGISTRATION NUMBER:  31,327
;      REFERENCE/DOCKET NUMBER:  NU-9033CIP
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  312/456-8000
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  5 amino acids
;      TYPE:  AMINO ACID
;      STRANDEDNESS:  unknown
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
US-07-934-553-2

  Query Match             90.9%;  Score 20;  DB 1;  Length 5;
  Best Local Similarity   80.0%;  Pred. No. 3e+05;
  Matches    4;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;
Qy          1 FXGLM 5
                | |||
Db          1 FFGLM 5
Search completed: April  7, 2004, 09:26:37
Job time : 32 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: April 7, 2004, 09:14:31 ; Search time 53 Seconds
(without alignments)
26.655 Million cell updates/sec

Title: US-10-030-388A-1
Perfect score: 22
Sequence: 1 FXGLM 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 447529

Minimum DB seq length: 0
Maximum DB seq length: 15

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 1000 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	21	95.5	12	2	AAW64648	Aaw64648 Synthetic
2	21	95.5	14	4	AAM97765	Aam97765 Human pep
3	20	90.9	5	2	AAR33009	Aar33009 Alpha-sub
4	20	90.9	5	2	AAR33008	Aar33008 Alpha-sub
5	20	90.9	5	2	AAR33007	Aar33007 Alpha-sub
6	20	90.9	5	2	AAR33010	Aar33010 Alpha-sub
7	20	90.9	5	2	AAW80134	Aaw80134 COOH-term
8	20	90.9	5	2	AAR54549	Aar54549 Cholecyst
9	20	90.9	5	2	AAR54551	Aar54551 Cholecyst

10	20	90.9	5	2	AAR54550	Aar54550 Cholecyst
11	20	90.9	5	2	AAR54548	Aar54548 Cholecyst
12	20	90.9	5	2	AAW41687	Aaw41687 Tetrapept
13	20	90.9	5	2	AAW99643	Aaw99643 Substance
14	20	90.9	5	2	AAY50325	Aay50325 Neutrophi
15	20	90.9	5	2	AAW92660	Aaw92660 Human tac
16	20	90.9	5	3	AAB23028	Aab23028 Mammalian
17	20	90.9	5	3	AAB23025	Aab23025 Human/rat
18	20	90.9	5	3	AAY67576	Aay67576 P antagon
19	20	90.9	5	4	AAB66674	Aab66674 C-termina
20	20	90.9	5	4	AAB82430	Aab82430 Fluorinat
21	20	90.9	5	4	AAB82431	Aab82431 Fluorinat
22	20	90.9	5	4	AAB91428	Aab91428 Tachykini
23	20	90.9	5	4	AAB70556	Aab70556 Octopus t
24	20	90.9	5	5	AAU10880	Aau10880 Human bet
25	20	90.9	5	5	ABB10088	Abb10088 Substance
26	20	90.9	5	5	AAU77847	Aau77847 Tachykini
27	20	90.9	5	5	AAU77845	Aau77845 Tachykini
28	20	90.9	5	7	ADC64000	Adc64000 Tachykini
29	20	90.9	6	1	AAP30443	Aap30443 Sequence
30	20	90.9	6	1	AAP40519	Aap40519 Sequence
31	20	90.9	6	1	AAP50694	Aap50694 Sequence
32	20	90.9	6	1	AAP50632	Aap50632 Substance
33	20	90.9	6	1	AAP61486	Aap61486 Peptide h
34	20	90.9	6	2	AAR07897	Aar07897 Cylcopept
35	20	90.9	6	2	AAR07893	Aar07893 Cylcopept
36	20	90.9	6	2	AAR21959	Aar21959 Substance
37	20	90.9	6	2	AAR27696	Aar27696 Cyclic ta
38	20	90.9	6	2	AAR27694	Aar27694 Cyclic ta
39	20	90.9	6	2	AAR27695	Aar27695 Cyclic ta
40	20	90.9	6	2	AAW99686	Aaw99686 Substance
41	20	90.9	6	2	AAW92706	Aaw92706 Human tac
42	20	90.9	6	2	AAW92659	Aaw92659 Human tac
43	20	90.9	6	2	AAY31052	Aay31052 Non-cross
44	20	90.9	6	3	AAY67575	Aay67575 P antagon
45	20	90.9	6	4	AAB82453	Aab82453 Fluorinat
46	20	90.9	6	4	AAB82432	Aab82432 Fluorinat
47	20	90.9	6	4	AAB82436	Aab82436 Fluorinat
48	20	90.9	6	4	AAB82433	Aab82433 Fluorinat
49	20	90.9	6	4	AAB91421	Aab91421 Tachykini
50	20	90.9	6	4	AAB91425	Aab91425 Tachykini
51	20	90.9	6	4	AAB91419	Aab91419 Tachykini
52	20	90.9	6	4	AAG99351	Aag99351 Atypical
53	20	90.9	6	4	AAB74306	Aab74306 Peptide a
54	20	90.9	6	4	AAB98884	Aab98884 Chimeric
55	20	90.9	6	4	AAB98886	Aab98886 Chimeric
56	20	90.9	6	5	ABB10087	Abb10087 Substance
57	20	90.9	6	5	ABB10086	Abb10086 Substance
58	20	90.9	6	6	ABJ37288	Abj37288 Rhodopsin
59	20	90.9	7	1	AAP20310	Aap20310 Tyr8-SP5-
60	20	90.9	7	2	AAR21956	Aar21956 Substance
61	20	90.9	7	2	AAR21957	Aar21957 Substance
62	20	90.9	7	2	AAW29539	Aaw29539 Asp-Ser-P
63	20	90.9	7	2	AAY50324	Aay50324 Neutrophi
64	20	90.9	7	2	AAW92662	Aaw92662 Human tac
65	20	90.9	7	2	AAW92705	Aaw92705 Human tac
66	20	90.9	7	3	AAY67574	Aay67574 P antagon

67	20	90.9	7	4	AAB80323	Aab80323 Human pro
68	20	90.9	7	4	AAB80324	Aab80324 Human pro
69	20	90.9	7	4	AAB82428	Aab82428 Fluorinat
70	20	90.9	7	4	AAB82429	Aab82429 Fluorinat
71	20	90.9	7	4	AAB91354	Aab91354 Tachykini
72	20	90.9	7	4	AAB91431	Aab91431 Tachykini
73	20	90.9	7	4	AAB91420	Aab91420 Tachykini
74	20	90.9	7	4	AAG99350	Aag99350 Atypical
75	20	90.9	7	4	AAB98845	Aab98845 Chimeric
76	20	90.9	7	5	ABB10085	Abb10085 Substance
77	20	90.9	7	5	ABB09500	Abb09500 Substance
78	20	90.9	8	1	AAP20303	Aap20303 Gastroint
79	20	90.9	8	2	AAR28444	Aar28444 Neurokini
80	20	90.9	8	2	AAW57536	Aaw57536 Molecular
81	20	90.9	8	2	AAW92664	Aaw92664 Human tac
82	20	90.9	8	2	AAW92710	Aaw92710 Human tac
83	20	90.9	8	3	AAY67573	Aay67573 P antagon
84	20	90.9	8	4	AAB91407	Aab91407 Tachykini
85	20	90.9	8	4	AAB91416	Aab91416 Tachykini
86	20	90.9	8	4	AAB91424	Aab91424 Tachykini
87	20	90.9	8	4	AAG99349	Aag99349 Atypical
88	20	90.9	8	4	AAB97571	Aab97571 Substitut
89	20	90.9	8	5	ABB09498	Abb09498 Substance
90	20	90.9	8	5	ABB09499	Abb09499 Substance
91	20	90.9	9	1	AAP50634	Aap50634 Substance
92	20	90.9	9	2	AAW92714	Aaw92714 Human tac
93	20	90.9	9	4	AAB80325	Aab80325 Human pro
94	20	90.9	9	4	AAB91446	Aab91446 Tachykini
95	20	90.9	9	4	AAB91369	Aab91369 Tachykini
96	20	90.9	9	4	AAG99348	Aag99348 Atypical
97	20	90.9	10	1	AAP40414	Aap40414 Decapepti
98	20	90.9	10	1	AAP40413	Aap40413 Decapepti
99	20	90.9	10	1	AAP50633	Aap50633 Substance
100	20	90.9	10	2	AAR21933	Aar21933 Substance
101	20	90.9	10	2	AAR65181	Aar65181 S. cerevi
102	20	90.9	10	2	AAR77311	Aar77311 Neurokini
103	20	90.9	10	2	AAR77312	Aar77312 Neurokini
104	20	90.9	10	2	AAW79777	Aaw79777 Neurokini
105	20	90.9	10	2	AAW79776	Aaw79776 Neurokini
106	20	90.9	10	2	AAW48951	Aaw48951 Tachykini
107	20	90.9	10	2	AAW75251	Aaw75251 Fragment
108	20	90.9	10	2	AAW74415	Aaw74415 HPMBQ91 p
109	20	90.9	10	2	AAY23264	Aay23264 Protein b
110	20	90.9	10	2	AAY06939	Aay06939 Substance
111	20	90.9	10	2	AAW92663	Aaw92663 Human tac
112	20	90.9	10	2	AAW92697	Aaw92697 Human tac
113	20	90.9	10	2	AAW92729	Aaw92729 Human tac
114	20	90.9	10	2	AAW92728	Aaw92728 Human tac
115	20	90.9	10	4	AAB82417	Aab82417 Neurokini
116	20	90.9	10	4	AAB91383	Aab91383 Tachykini
117	20	90.9	10	4	AAB91398	Aab91398 Tachykini
118	20	90.9	10	4	AAB91355	Aab91355 Tachykini
119	20	90.9	10	4	AAB91397	Aab91397 Tachykini
120	20	90.9	10	4	AAB91368	Aab91368 Tachykini
121	20	90.9	10	4	AAB91445	Aab91445 Tachykini
122	20	90.9	10	4	AAB91356	Aab91356 Tachykini
123	20	90.9	10	4	AAG99355	Aag99355 Neurokini

124	20	90.9	10	4	AAG99356	Aag99356 Neurokini
125	20	90.9	10	4	AAG99347	Aag99347 Atypical
126	20	90.9	10	4	AAG64746	Aag64746 Substance
127	20	90.9	10	4	AAB82381	Aab82381 Human neu
128	20	90.9	10	5	AAE27017	Aae27017 Human gen
129	20	90.9	10	5	AAE27155	Aae27155 Human gen
130	20	90.9	10	5	ABB99004	Abb99004 Neurokini
131	20	90.9	10	5	ABB99003	Abb99003 Neurokini
132	20	90.9	10	6	ABG76074	Abg76074 Sea lampr
133	20	90.9	10	6	ABU65028	Abu65028 Human sec
134	20	90.9	10	7	ADC63999	Adc63999 Mosquito
135	20	90.9	10	7	ADC63998	Adc63998 Mosquito
136	20	90.9	11	1	AAP50425	Aap50425 Hypotensi
137	20	90.9	11	1	AAP61480	Aap61480 Sequence
138	20	90.9	11	1	AAP80312	Aap80312 Sequence
139	20	90.9	11	2	AAR11854	Aar11854 Undecapep
140	20	90.9	11	2	AAR13162	Aar13162 Sialic ac
141	20	90.9	11	2	AAR28445	Aar28445 Neurokini
142	20	90.9	11	2	AAR28442	Aar28442 Substance
143	20	90.9	11	2	AAR21971	Aar21971 Cyclic su
144	20	90.9	11	2	AAR21942	Aar21942 Substance
145	20	90.9	11	2	AAR21962	Aar21962 Substance
146	20	90.9	11	2	AAR21945	Aar21945 Substance
147	20	90.9	11	2	AAR21963	Aar21963 Substance
148	20	90.9	11	2	AAR21949	Aar21949 Substance
149	20	90.9	11	2	AAR21951	Aar21951 Substance
150	20	90.9	11	2	AAR21946	Aar21946 Substance
151	20	90.9	11	2	AAR21964	Aar21964 Substance
152	20	90.9	11	2	AAR21972	Aar21972 Cyclic su
153	20	90.9	11	2	AAR21970	Aar21970 Cyclic su
154	20	90.9	11	2	AAR21938	Aar21938 Substance
155	20	90.9	11	2	AAR21941	Aar21941 Substance
156	20	90.9	11	2	AAR21939	Aar21939 Substance
157	20	90.9	11	2	AAR21954	Aar21954 Substance
158	20	90.9	11	2	AAR42646	Aar42646 Neurokini
159	20	90.9	11	2	AAR42649	Aar42649 Neurokini
160	20	90.9	11	2	AAR32183	Aar32183 Ranakinin
161	20	90.9	11	2	AAR32182	Aar32182 Generic n
162	20	90.9	11	2	AAR85243	Aar85243 Substance
163	20	90.9	11	2	AAR77109	Aar77109 Uperoleia
164	20	90.9	11	2	AAR77310	Aar77310 Substance
165	20	90.9	11	2	AAW33181	Aaw33181 Mono-DTPA
166	20	90.9	11	2	AAW33180	Aaw33180 Mono-DTPA
167	20	90.9	11	2	AAW04616	Aaw04616 Substance
168	20	90.9	11	2	AAW04613	Aaw04613 Physalaem
169	20	90.9	11	2	AAW79775	Aaw79775 Substance
170	20	90.9	11	2	AAW42973	Aaw42973 Substrate
171	20	90.9	11	2	AAW48950	Aaw48950 Tachykini
172	20	90.9	11	2	AAW48280	Aaw48280 Tyrosylpe
173	20	90.9	11	2	AAW79663	Aaw79663 Substance
174	20	90.9	11	2	AAW79662	Aaw79662 Substance
175	20	90.9	11	2	AAW92679	Aaw92679 Human tac
176	20	90.9	11	2	AAW92676	Aaw92676 Human tac
177	20	90.9	11	2	AAW92720	Aaw92720 Human tac
178	20	90.9	11	2	AAW92673	Aaw92673 Human tac
179	20	90.9	11	2	AAW92708	Aaw92708 Human tac
180	20	90.9	11	2	AAW92731	Aaw92731 Human tac

181	20	90.9	11	2	AAW92670	Aaw92670 Human tac
182	20	90.9	11	2	AAW92689	Aaw92689 Human tac
183	20	90.9	11	2	AAW92715	Aaw92715 Human tac
184	20	90.9	11	2	AAW92719	Aaw92719 Human tac
185	20	90.9	11	2	AAW92727	Aaw92727 Human tac
186	20	90.9	11	2	AAW92680	Aaw92680 Human tac
187	20	90.9	11	2	AAW92692	Aaw92692 Human tac
188	20	90.9	11	2	AAW92681	Aaw92681 Human tac
189	20	90.9	11	2	AAW92669	Aaw92669 Human tac
190	20	90.9	11	2	AAW92691	Aaw92691 Human tac
191	20	90.9	11	2	AAW92672	Aaw92672 Human tac
192	20	90.9	11	2	AAW92690	Aaw92690 Human tac
193	20	90.9	11	2	AAY30985	Aay30985 Non-cross
194	20	90.9	11	2	AAY03156	Aay03156 Substance
195	20	90.9	11	3	AAB23027	Aab23027 Human/rat
196	20	90.9	11	3	AAB18483	Aab18483 Peptide s
197	20	90.9	11	3	AAY67965	Aay67965 Carboxyfl
198	20	90.9	11	3	AAY32382	Aay32382 Cell diff
199	20	90.9	11	3	AAB06260	Aab06260 Substance
200	20	90.9	11	3	AAB08614	Aab08614 Peptide i
201	20	90.9	11	4	AAB50311	Aab50311 Previn pe
202	20	90.9	11	4	AAB50312	Aab50312 Previn pe
203	20	90.9	11	4	AAB50306	Aab50306 Substance
204	20	90.9	11	4	AAB50316	Aab50316 Previn pe
205	20	90.9	11	4	AAB50544	Aab50544 Prolyl en
206	20	90.9	11	4	AAB91371	Aab91371 Tachykini
207	20	90.9	11	4	AAB91357	Aab91357 Tachykini
208	20	90.9	11	4	AAB91409	Aab91409 Tachykini
209	20	90.9	11	4	AAB91450	Aab91450 Tachykini
210	20	90.9	11	4	AAB91438	Aab91438 Tachykini
211	20	90.9	11	4	AAB91449	Aab91449 Tachykini
212	20	90.9	11	4	AAB91437	Aab91437 Tachykini
213	20	90.9	11	4	AAB91351	Aab91351 Tachykini
214	20	90.9	11	4	AAB91386	Aab91386 Tachykini
215	20	90.9	11	4	AAB91402	Aab91402 Tachykini
216	20	90.9	11	4	AAB91436	Aab91436 Tachykini
217	20	90.9	11	4	AAG99358	Aag99358 ATT-short
218	20	90.9	11	4	AAG99354	Aag99354 Substance
219	20	90.9	11	4	AAG99337	Aag99337 Human aty
220	20	90.9	11	4	AAU07298	Aau07298 Substance
221	20	90.9	11	4	AAG62768	Aag62768 Amino aci
222	20	90.9	11	4	AAB84527	Aab84527 Amino aci
223	20	90.9	11	4	AAB49755	Aab49755 Complex s
224	20	90.9	11	4	AAB98866	Aab98866 Chimeric
225	20	90.9	11	4	AAB82070	Aab82070 Substance
226	20	90.9	11	5	ABB75676	Abb75676 Pseudo-me
227	20	90.9	11	5	AAO17685	Aao17685 Equine gu
228	20	90.9	11	5	AAU85994	Aau85994 Modified
229	20	90.9	11	5	ABB09496	Abb09496 Substance
230	20	90.9	11	5	ABB09481	Abb09481 Substance
231	20	90.9	11	5	AAU96752	Aau96752 Substance
232	20	90.9	11	5	AAU77844	Aau77844 Tachykini
233	20	90.9	11	5	AAE19492	Aae19492 Substance
234	20	90.9	11	5	AAU91346	Aau91346 Substance
235	20	90.9	11	5	AAU10409	Aau10409 Subtance-
236	20	90.9	11	5	AAO15554	Aao15554 Human Sub
237	20	90.9	11	5	ABB99002	Abb99002 Substance

238	20	90.9	11	5	ABB09842	Abb09842 Amino aci
239	20	90.9	11	6	ABP72531	Abp72531 Substance
240	20	90.9	11	6	ABG76071	Abg76071 Chicken a
241	20	90.9	11	6	ABG76064	Abg76064 Human tac
242	20	90.9	11	6	ABG76073	Abg76073 Rainbow t
243	20	90.9	11	6	ABG76069	Abg76069 Spotted d
244	20	90.9	11	6	ABG76070	Abg76070 Guinea pi
245	20	90.9	11	6	ABG76072	Abg76072 Atlantic
246	20	90.9	11	7	ADD69983	Add69983 Primate n
247	20	90.9	11	7	ABR83030	Abr83030 Substance
248	20	90.9	12	2	AAR32798	Aar32798 Tyr-1 sub
249	20	90.9	12	2	AAR85244	Aar85244 Substance
250	20	90.9	12	2	AAW04615	Aaw04615 Kassinin
251	20	90.9	12	2	AAW94412	Aaw94412 Cancer pr
252	20	90.9	12	2	AAW92730	Aaw92730 Human tac
253	20	90.9	12	2	AAY03157	Aay03157 Substance
254	20	90.9	12	4	AAB92032	Aab92032 Galanin p
255	20	90.9	12	4	AAB70553	Aab70553 Octopus t
256	20	90.9	12	4	AAB70557	Aab70557 Octopus t
257	20	90.9	12	4	AAB70554	Aab70554 Octopus t
258	20	90.9	12	4	AAG62772	Aag62772 Amino aci
259	20	90.9	12	4	AAG62775	Aag62775 Amino aci
260	20	90.9	12	4	AAG62769	Aag62769 Amino aci
261	20	90.9	12	4	AAB84528	Aab84528 Amino aci
262	20	90.9	12	4	AAB98873	Aab98873 Chimeric
263	20	90.9	12	4	AAB98870	Aab98870 Chimeric
264	20	90.9	12	4	AAB98867	Aab98867 Chimeric
265	20	90.9	12	5	ABB09480	Abb09480 Substance
266	20	90.9	12	5	AAU96753	Aau96753 Substance
267	20	90.9	12	5	AAU96756	Aau96756 Substance
268	20	90.9	12	5	ABB04922	Abb04922 Memory-en
269	20	90.9	12	5	AAE19496	Aae19496 Substance
270	20	90.9	12	5	AAE19499	Aae19499 Substance
271	20	90.9	12	5	AAE19493	Aae19493 Substance
272	20	90.9	12	7	ABR84705	Abr84705 Aggrecana
273	20	90.9	13	2	AAR29593	Aar29593 Vertebrat
274	20	90.9	13	2	AAW92700	Aaw92700 Human tac
275	20	90.9	13	2	AAY03158	Aay03158 Substance
276	20	90.9	13	4	AAG62773	Aag62773 Amino aci
277	20	90.9	13	4	AAG62770	Aag62770 Amino aci
278	20	90.9	13	4	AAG62776	Aag62776 Amino aci
279	20	90.9	13	4	AAB98874	Aab98874 Chimeric
280	20	90.9	13	4	AAB98871	Aab98871 Chimeric
281	20	90.9	13	4	AAB98868	Aab98868 Chimeric
282	20	90.9	13	5	AAU96757	Aau96757 Substance
283	20	90.9	13	5	AAU96754	Aau96754 Substance
284	20	90.9	13	5	AAE19494	Aae19494 Substance
285	20	90.9	13	5	AAE19497	Aae19497 Substance
286	20	90.9	13	5	AAE19500	Aae19500 Substance
287	20	90.9	14	2	AAY03159	Aay03159 Substance
288	20	90.9	14	4	AAB91440	Aab91440 Tachykini
289	20	90.9	14	4	AAG62771	Aag62771 Amino aci
290	20	90.9	14	4	AAG62777	Aag62777 Amino aci
291	20	90.9	14	4	AAG62774	Aag62774 Amino aci
292	20	90.9	14	4	AAB98872	Aab98872 Chimeric
293	20	90.9	14	4	AAB98869	Aab98869 Chimeric
294	20	90.9	14	4	AAB98875	Aab98875 Chimeric

295	20	90.9	14	5	AAU96755	Aau96755 Substance
296	20	90.9	14	5	AAU96758	Aau96758 Substance
297	20	90.9	14	5	AAE19498	Aae19498 Substance
298	20	90.9	14	5	AAE19495	Aae19495 Substance
299	20	90.9	14	5	AAE19501	Aae19501 Substance
300	20	90.9	14	6	ABP56241	Abp56241 Targeting
301	20	90.9	14	8	ADE64332	Ade64332 Radiophar
302	20	90.9	15	2	AAW75250	Aaw75250 Fragment
303	20	90.9	15	5	AAE27016	Aae27016 Human gen
304	20	90.9	15	5	AAE27154	Aae27154 Human gen
305	20	90.9	15	6	ABU65027	Abu65027 Human sec
306	19	86.4	10	2	AAW92698	Aaw92698 Human tac
307	19	86.4	10	2	AAW92696	Aaw92696 Human tac
308	19	86.4	10	4	AAB91370	Aab91370 Tachykini
309	19	86.4	11	2	AAR21968	Aar21968 Cyclic su
310	19	86.4	11	2	AAW92687	Aaw92687 Human tac
311	19	86.4	11	4	AAB50314	Aab50314 Previn pe
312	19	86.4	11	4	AAB50315	Aab50315 Previn pe
313	19	86.4	11	4	AAB50313	Aab50313 Previn pe
314	19	86.4	14	2	AAW47171	Aaw47171 Antigenic
315	19	86.4	14	3	AAB01939	Aab01939 MAb 12f3.
316	19	86.4	14	4	AAE12476	Aae12476 XMEL anti
317	19	86.4	14	5	AAE26378	Aae26378 Melag 7 a
318	19	86.4	14	6	ABG72920	Abg72920 Anti-mrk-
319	18	81.8	9	2	AAW45712	Aaw45712 MAGE-3 19
320	18	81.8	10	7	ADD94752	Add94752 Human SIM
321	18	81.8	10	7	ADD94536	Add94536 Human SIM
322	18	81.8	10	7	ADD94736	Add94736 Human SIM
323	18	81.8	10	7	ADD94724	Add94724 Human SIM
324	18	81.8	10	7	ADD94684	Add94684 Human SIM
325	18	81.8	10	7	ADD94543	Add94543 Human SIM
326	18	81.8	12	1	AAP50357	Aap50357 Hylambati
327	18	81.8	12	2	AAW79348	Aaw79348 Staphyloc
328	18	81.8	15	4	AAB67932	Aab67932 Internal
329	17	77.3	5	2	AAW92702	Aaw92702 Human tac
330	17	77.3	5	4	AAG99352	Aag99352 Atypical
331	17	77.3	5	4	AAG99346	Aag99346 Atypical
332	17	77.3	5	5	AAG80461	Aag80461 Enzyme cl
333	17	77.3	5	5	ABB10089	Abb10089 Substance
334	17	77.3	6	2	AAW29545	Aaw29545 Suc(psi(C
335	17	77.3	6	2	AAY22121	Aay22121 Human uri
336	17	77.3	6	4	AAB82442	Aab82442 Fluorinat
337	17	77.3	6	4	AAB82421	Aab82421 Fluorinat
338	17	77.3	6	4	AAB82449	Aab82449 Fluorinat
339	17	77.3	6	4	AAB82420	Aab82420 Fluorinat
340	17	77.3	6	4	AAB82450	Aab82450 Fluorinat
341	17	77.3	7	2	AAW29544	Aaw29544 Asp-Ser(p
342	17	77.3	7	2	AAW29543	Aaw29543 Asp-Ser-P
343	17	77.3	7	2	AAW29547	Aaw29547 Asp-Ser-P
344	17	77.3	7	2	AAW29540	Aaw29540 Asp-Ser-P
345	17	77.3	7	4	AAB82418	Aab82418 Fluorinat
346	17	77.3	7	4	AAB82437	Aab82437 Fluorinat
347	17	77.3	7	4	AAB82445	Aab82445 Fluorinat
348	17	77.3	7	4	AAB82446	Aab82446 Fluorinat
349	17	77.3	7	4	AAB82424	Aab82424 Fluorinat
350	17	77.3	7	4	AAB82419	Aab82419 Fluorinat
351	17	77.3	7	4	AAB82425	Aab82425 Fluorinat

ALIGNMENTS

RESULT 1
AAW64648
ID AAW64648 standard; peptide; 12 AA.
XX
AC AAW64648;
XX
DT 23-OCT-1998 (first entry)
XX
DE Synthetic SEB-related peptide (position 13-24).
XX
KW Enterotoxin B; SEB; pyrogenic exotoxin; PET; protective immunity;
KW toxic shock; toxin-mediated activation; T-cell; antagonist; inhibitor;
KW therapeutic; vaccine; food poisoning.
XX
OS Synthetic.
OS Staphylococcus aureus.
XX
PN WO9829444-A1.
XX
PD 09-JUL-1998.
XX
PF 30-DEC-1997; 97WO-IL000438.
XX
PR 30-DEC-1996; 96IL-00119938.
XX
PA (YISS) YISSUM RES & DEV CO.
XX
PI Kaempfer R, Arad G;
XX
DR WPI; 1998-388042/33.
XX
PT New peptide(s) derived from pyrogenic exotoxin - useful for, e.g.
PT antagonising toxin-mediated activation of T cells and prevention or
PT treatment of toxic shock caused by exotoxin(s).
XX
PS Example 2; Page 38; 68pp; English.
XX
CC AAW64636-W64657 are peptides homologous to the amino acid sequence of a
CC fragment of a pyrogenic exotoxin (PET), and derivatives of the peptide
CC capable of eliciting protective immunity against toxic shock induced by
CC PET or by a mixture of PETs. Such peptides are also capable of
CC antagonising toxin-mediated activation of T-cells, inhibiting expression
CC of pyrogenic toxin (PT)-induced mRNA encoded by IL-2, IFN-gamma or TNF-
CC beta genes. The peptides may be used to prepare therapeutics or vaccines
CC for the treatment of prophylaxis of toxin-mediated activation of T cells
CC and eliciting protective immunity against toxic shock induced by PETs.
CC They can also be used for the treatment of harmful effects (especially
CC food poisoning) and toxic shock caused by PET. Antiserum to the peptides
CC can also be used for alleviating toxic shock induced by PET
XX
SQ Sequence 12 AA;

  Query Match 95.5%; Score 21; DB 2; Length 12;

Best Local Similarity 80.0%; Pred. No. 82;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 FXGLM 5
              | |||
Db          5 FTGLM 9
```

RESULT 2
AAM97765
ID AAM97765 standard; peptide; 14 AA.
XX
AC AAM97765;
XX
DT 24-JAN-2002 (first entry)
XX
DE Human peptide #1040 encoded by a SNP oligonucleotide.
XX
KW Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;
KW neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;
KW amyloid protein; angiopoietin; apoptosis related protein; cadherin;
KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KW complement related protein; cytochrome; kinesin; cytokine; interferon;
KW interleukin; G-protein coupled receptor; thioesterase; inflammation;
KW multifactorial disease; autoimmune disease; infection;
KW nervous system disease.
XX
OS Homo sapiens.
XX
PN WO200147944-A2.
XX
PD 05-JUL-2001.
XX
PF 28-DEC-2000; 2000WO-US035498.
XX
PR 28-DEC-1999; 99US-0173419P.
PR 27-DEC-2000; 2000US-00173419.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach M;
XX
DR WPI; 2001-465210/50.
XX
PT Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,
PT oncogenes and histones, useful for diagnosing and treating, e.g. cancer,
PT autoimmune diseases and infections.
XX
PS Disclosure; Page 3895; 4143pp; English.
XX
CC The present invention relates to oligonucleotides (see AAL26793-AAL34659)
CC encoding polymorphic variants of proteins related to amylases, amyloid
CC proteins, angiopoietin, apoptosis related proteins, cadherin, cyclin,
CC polymerase, oncogenes, histones, kinases, colony stimulating factors,
CC complement related proteins, cytochromes, kinesins, cytokines,
CC interferons, interleukins, G-protein coupled receptors and thioesterases.
CC The present sequence is a peptide encoded by one such oligonucleotide.

CC The oligonucleotides and the peptides encoded by them may be used in the
CC prevention, diagnosis and treatment of diseases associated with
CC inappropriate expression of the proteins listed above. Disorders that may
CC be prevented, diagnosed and/or treated include multifactorial diseases
CC with a genetic component, such as autoimmune diseases (e.g. rheumatoid
CC arthritis, multiple sclerosis, diabetes, systemic lupus erythromatosus
CC and Grave's disease), inflammation, cancer (e.g. cancers of the bladder,
CC brain, breast, colon and kidney, leukaemia), diseases of the nervous
CC system and an infection of pathogenic organisms
XX
SQ Sequence 14 AA;

Query Match 95.5%; Score 21; DB 4; Length 14;
Best Local Similarity 80.0%; Pred. No. 95;
Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 FXGLM 5
              | |||
Db          9 FSGLM 13
```

Search completed: April 7, 2004, 09:24:58
Job time : 75 secs